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 Nuclear receptors are ligand activated transcription factors that are widely distributed 
throughout the mammalians. There are 48 known human nuclear receptors within the body 
located in various systems. While some nuclear receptors can be located wholly within certain 
regions and tissues the clear majority are widely distributed, overlapping expression in the same 
locations. The role of nuclear receptors as transcription factors has caused them to be implicated 
in a vast number of diseases including metabolic, cardiovascular and neurological. The role of 
nuclear receptors in diseases and the potential to promote ligand activated transcription makes 
nuclear receptors of pharmaceutical significance. Currently it is estimated that 33% of nuclear 
receptors are targeted by the pharmaceutical industry resulting in ~20% of pharmaceutical 
development worldwide. The potential to control physiological responses via introduction of a 
ligand to nuclear receptors has continued the interest in development of new ligands to further 
the understanding of nuclear receptor behavior. The challenge nuclear receptors present is to 
develop ligands that are selective in targeting within families and among different classes of 
nuclear receptors.  
At the core, ligand activated nuclear receptor modulation is chiefly centered around the 
relationship between the ligand binding pocket of the receptor and the ligand. Composed 
primarily of non-polar amino acid residues the ligand binding pocket is the cavity by which 
small hydrophobic molecules bind. Demonstrating large variance across classes of nuclear 
receptor and little divergence within families the ligand binding pocket serves as the focal point 
for targeting selectivity. Successful binding and thus receptor response is contingent upon the 
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ligand meeting criteria established by the ligand binding pocket such as satisfactory size/volume 
of the ligand and key ligand-receptor amino acid residue interaction.  Research conducted by 
Katzenellenbogen was paramount in understanding the relationship between the estrogen 
receptors and its ligands. His established pharmacophore unraveled features for potential ligands 
that are exchangeable from those that are indispensable. The commercial success of estrogen 
receptor ligands has fueled the interest in not only understanding ligand-receptor binding 
interactions but its subcellular movement.  
The Green Fluorescent Protein completely revolutionized the way in which cellular probing is 
conducted. The chromophore internally synthesized by the protein through a series of folding of 
amino acid residues afforded the opportunity to monitor cellular movements with the aid of 
fluorescence. Commonly utilized in visualization as a fusion protein, the GFP chromophore 
provided the ideal tool for understanding protein cellular movement and interaction. Simply put 
due to the chromophore that resides at the center, GFP provides the perfect technique for cellular 
probing.      
Here in we report the use of GFP-chromophore inspired ligands for utility as estrogen receptor 
agonist. By utilizing the GFP chromophore skeleton as a template for ligand development the 
potential arises for the molecule to co-function as a receptor binder and probe. The use of the 
GFP-chromophore skeleton boasts several advantages in addition to synthetic amenable features 
the arymethyleneimidazolone core maintains the same frame work as Katzenellenbogen’s 
proposed pharmacophore. Through the lens of Katzenellenbogen’s consideration and the use of a 
simple but elegant synthesis a small library of GFP chromophore inspired 
arylmethyleneimidazolone ligands were synthesized, screened for selective estrogen receptor 
activation and tested both in vivo and in vitro for cellular probing applications.  
xxi 
 
Through this work we identified a set of 10 ligands that serve as agonist for the estrogen 
receptor. Although of the 10 ligands several demonstrate activation for both ERα and ERβ, a 
high degree of preference for ERα is observed. Of the ligands screened all estrogen receptor 
active ligands were nuclear receptor selective failing to activate other receptors such as RAR and 
RXR. Biological screening also uncovered a super agonist in CW32 that demonstrated the 
highest level of activation. Though a structure activity relationship model was established for top 
activators and additional generations synthesized no compound was found to be more active than 
CW32. While the majority of ligands displayed a preferential affinity for ERα ligand CW72 
demonstrated complete specificity for ERα. All ligands were confirmed through TRFRET as 
binding in the same ligand binding pocket as estradiol. Computational modeling supports the 
rationale that the following three criteria governed the ligands ability to successfully bind: 1) 
hydrogen bonding network, 2) ligand size/volume and 3) molecular topology.  
Embracing the ligands skeleton originating from the Green fluorescent chromophore ligands that 
demonstrated ER activation were visualized under confocal both with in vivo and in vitro 
systems. Several ligands successfully demonstrated the ability to turn on fluorescence in 
responds to binding in vitro. While other ligands failed to display fluorescence in conjunction 
with binding. Despite all binders displaying fluorescence this represent a class of ligand that can 










Ligand design and target selection rest at the center of drug discovery and development however 
each stage presents its own set of challenges and obstacles [1]. The drug discovery process can 
be unsuccessful for multiple reasons including screening, potency and selectivity among the 
most common complications. These hardships are typically encountered early in the process such 
as during screening if available. To adequately evaluate the ligands ability to influence a 
biological system a model for assessing must be developed, however not all models include the 
target [2]. Exclusion of the target from the screening process at times can give an inadequate 
representation of results such as potency and selectivity [2]. Promiscuity in physiological 
response is often a result of the ligand interacting with alternative bio-factors in addition to the 
target. Ligand selectivity is of prime importance ideally the ligand should only activate the 
desired target. In the case of protein targets not only must selectivity be generated from similar 
classes of protein but diverging proteins within the class must be accounted for as well. The 
ligands ability to interact with a biochemical target is a critical early step in the process of 
promoting physiological response, more insight in the cellular behavior could yield creation of 
ligands with high degree of selectivity.      
A better understanding of the ligand-target complex is often achieved with fluorescently tagged 
ligands for cellular tracking and visualization. This common practice provides insight into both 
ligand movement and target location within tissue [3]. Once the ligand complexes with its target 
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additional information can be gained about the ligand-target complex and its post translational 
movement. The insight provided by fluorescently labeling the ligand can aid in re-designing of 
ligands that are more target specific and possibly tissue selective potentially resulting in 
diminishing of undesired biological responses. While tracking and visualization through the 
addition of a fluorescent tag is resourceful and insightful it is not without its drawbacks. The 
addition of a tag increases the ligands natural size which may adversely affect solubility of the 
ligand, ability to interact with binding sites of the target, and biological uptake of the ligand. 
Biological targets act in concert with larger systems, many undergo folding or some form of 
change after coupling with a ligand such proteins. The additional size added from the tag may 
restrict the protein or target from undergoing its natural conformation change thus altering its 
physiological response or biological process.   
The intent of this thesis is to convey the use of arylmethyleneimidazolone skeleton inspired by 
the green fluorescent protein chromophore as ligands that are potent, selective and provide 
tracking without a tag. Previously conducted work by Dr. Anna Duraj-Thatte [4] and Dr. 
Anthony Baldrige [5] identified nuclear receptors as a class of targets, for the scope of this thesis 
the estrogen receptor was selected as target of interest. By utilizing the chromophore of the green 
fluorescent protein as the backbone structure for our ligand design we adopt a structure with 
known fluorescence capability and strong precedence for uptake by proteins since chromophore 
formation occurs within the protein [3,6-8]. The overall driving question was can the 
chromophore inspired skeleton be an activating ligand, be selective, and maintain intrinsic photo-
physic properties that could be used for visualization? To test this hypothesis 3 research aims 




1.1.1 Designing of a potent estrogen receptor agonist            
Research Aim 1: Design of a potent estrogen receptor agonist 
Initial efforts in identifying a lead for this class of ligand started with results of an unpublished 
screening by our lab [4]. A library of GFP chromophore inspired ligands was screened for 
estrogen receptor activity via two methods yeasts three hybrid assay and luciferase assay. While 
the results indicated activity in seven ligands only two demonstrated activation significant 
enough to prompt further investigation as a lead compound. Of the over 100 compounds 
screened for estrogen receptor α AB 18 shown in figure 1.1 was selected as the lead due to an 
activation level 67% that of estradiol, the indigenous ligand.  
 
Figure 1.1 Lead Development for Research Aim 1. Development of Aim 1through surveying of 
known estrogen receptor agonist to build commonalities highlighted in red and blue into the 
GFP-inspired estrogen receptor agonist.   
Using AB18 as a lead, structural characteristics of known estrogen receptor ligands were 
surveyed to understand pre-requisites for binding. The objective was to design and synthesize 
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ligands that would not only bind but maximize receptor-ligand interactions in a hope to enhance 
potency. This stage is set to be an iterative process between ligand generation and ligand 
screening with the goal of developing a functional structure activity relationship ultimately 
resulting in a highly potent estrogen receptor ligand.  
1.1.2 Promoting selectivity within isotypes and among nuclear receptors          
Research Aim 2: Promote selectivity within estrogen receptor isotype and among other nuclear 
receptors. 
To test the hypothesis that this class of ERα ligand can be isotype and receptor selective all 
ligands deemed active during aim one will be screened for selectivity first within the estrogen 
receptor isotype and secondly among other nuclear receptors. The approach will be to compare 
the ligand binding domains of estrogen receptor subtype β with that of estrogen receptor α for 
features that could be exploited to promote selectivity. Structural differences of ligands will also 
be examined with attention devoted to ligands that have demonstrated isotype selectivity. The 
information learned in aim 1 in conjunction with revelation of estrogen receptor β ligand binding 
domain will be used to design and synthesize additional compounds aimed to promote selectivity 
while maintaining high activation.   
 
    ERα    ERβ 
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Figure 1.2 Estrogen receptors ligand binding domains complexed with ligand. Diversity can be 
seen between the estrogen receptors ligand binding domain and interactions with ligands 
providing an avenue for design of selective ligands. Labels for residues within the ligand binding 
pocket 4 Angstroms away from the ligand are included. The image on the left shows the ligand 
binding domain for ERα complexed with estradiol. The right illustrates ERβ ligand binding 
domain. Figure generated using Pymol with proteins from PDB 
  
In addition to ERβ, selectivity will be pursued across various nuclear receptor families such as 
retinoic x receptor α and retinoic acid receptor γ chosen for heterodimerization ability [9] and 
role in cancer [10] respectively. The approach will employ exploiting the variance that exist 
between ligand binding domains of different nuclear receptor families. Only ligands showing 
activation through aim 1 or initial phase of aim 2 will be screened in chemical complementation 
for retinoic x receptor α and retinoic acid receptor γ. Moving forward only active ligands will be 
utilized in proceeding aims.  
 
Figure 1.3 Ligand binding domains of additional nuclear receptors complexed with ligands. 
Image on the left shows retinoid X receptor ligand binding domain complexed with 9-cis retinoic 
acid while image on the right shows retinoic acid receptor complexed with 9-cis retinoic acid. By 
exploiting differences within the pockets of nuclear receptor ligand selectivity can be generated 
for additional categories of receptors. Figure generated using Pymol with proteins from PDB 
 
1.1.3 Accessing the role of florescence and activation  
Research Aim 3: Access the role of florescence and activation with chromophore inspired 
ligands. 
    RXRα    RARγ 
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To investigate the hypothesis that this class of ligand can be utilized as cellular probes, ligands 
identified as active will be subject to visualization via confocal microscopy. Visualizing active 
ligands both in the absence and presence of the estrogen receptor α ligand binding domain and 
cells will provide the opportunity to examine if fluorescence can be observed in active ligands 
only upon binding or is fluorescence achieved independent of a binding environment. The 
successful accomplishment of this aim will promote a ligand that not only binds but can be used 
for cellular tracking of the estrogen receptor α without traditional fluorescent labels used for 
estrogen receptor ligand agonist. 
 
Figure 1.4 Turn on of GFP inspired chromophore fluorescence via binding to estrogen receptor 
α. In the absence of the protein ideally the chromophore should not be activated. Upon binding 
of the ligand torsional strain should re-activate intrinsic fluorescence properties tying binding 
and fluorescence together. 
     
The overall project presents several points of novelty while other similar ring systems have been 
utilized including 2-Arylindene-1-ones [11] and simple benzamides [12] to our knowledge this is 
the first class of green fluorescent protein inspired ligands for the estrogen receptor α agonist. 
Likewise, while green fluorescent protein has significant applications as a molecular probe the 
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ideal of utilizing the chromophore in the absence of the protein as a cellular probe and as nuclear 
receptor activator strengthens the originality of this research. 
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 GREEN FLUORESCENT PROTEIN 
 
 
2.1  Historical Perspective  
 
Since its discovery and identification, the green fluorescent protein has catapulted into the 
spotlight and become one of the most widely explored and utilized proteins in cell biology and 
biochemistry [1]. Pioneered by several key figures the revolution induced by GFP in fluorescent 
proteins as biological tools resulted in the awarding of the Nobel Prize in chemistry in 2008 to 
select foundational contributors.  
Discovered in 1961 by Osamu Shimomura [2] from the jelly fish Aequorea aequorea (Aequorea 
victoria) GFP was initially described as a green fluorescence that occurred when Aequorea 
where irradiated with ultraviolet light [3].  Soon after its initial discovery GFP was identified as a 
protein [4] and renamed from “green protein” to its current nomenclature green fluorescent 
protein [5]. In 1979 the structure of the chromophore that gave rise to the fluorescence was 
characterized [6]. 
                                  
Aequorea Victoria photo courtesy of Glebstock-Fotolia     
Figure 2.1 Aequorea victoria displaying fluorescence. GFP is responsible for the observed 




 Accumulation of small amounts of GFP afforded Shimomura the opportunity to conduct a series 
of experiments including enzymic digestion, peptide isolation and purification. Spectroscopic 
analysis in conjunction with comparison of absorption spectra of previous compounds 
Shimomura synthesized, ultimately led to the deduction of the chromophore structure. 
Characterization of the chromophore revealed that fluorescence was not a result of a complex or 
association of a secondary organism, but amino acids encoded in the primary sequence of the 
protein that allowed the protein to autocatalyze the formation of its own fluorophore. This 
discovery cleared the path for the possibility of cloning the protein without infringing upon its 
fluorescent properties.  In 1985 aequorin was cloned and expressed shortly thereafter GFP was 
cloned [7, 8, 9, 10] which expedited the progression of GFP. Over the next several years’ 
advancements in GFP discoveries flourished including the confirmation of Shimomura proposed 
chromophore structure and flanking amino acids [11], GFP expression in E. coli [12], and crystal 
structure of wild type GFP [13]. In the years to follow the discovery of GFP and its chromophore 
paved the way for discoveries of additional fluorescent proteins [14] which will be discussed 
later in this chapter. Cloning and expression eased the accessibility of GFP thus encouraging 
novel applications in cell biology and visual development with pioneering studies being 
conducted in GFP lasers [15] and cellular tracking.     
 
2.2  Green Fluorescent Protein 
Bioluminescence can be defined as the emission of light by a living organism as a resultant of a 
chemical reaction [16]. The production of bioluminescence can broadly be described as 
occurring via the oxidation of a substrate termed the luciferin by an enzyme referred to as the 
luciferase. While bioluminescence is not confined to any specific environment it is estimated that 
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90% of deep sea marine life produce bioluminescence [16]. Observed in bacteria, algae, 
crustaceans, jellyfish, sea stars and squids it is postulated that the light producing reaction serves 
as a survival tool to lure prey, elude predators, or allure a mate in all bioluminescence can 
certainly be viewed as elegant communication.   
Bioluminescence has been studied in many marine organisms among the most notable is the 
jellyfish Aequorea victoria. Reported in 1955, Aequorea victoria fluoresced green when irritated 
with ultraviolet light, later it was discovered that luminescence and green fluorescence could be 
attributed to two proteins Aequorin and green fluorescent protein [3]. Aequorin is a calcium 
sensitive protein probe characterized by two features its calcium binding region and 
coelenterazine its prosthetic group [17]. Upon binding of calcium ions conformational changes 
occur within the apoaequorin (luciferase) causing the oxidation of the coelenterazine substrate 
(luciferin) [17]. The transition of the substrate from its excited state (coelenteramide) back to its 
relaxed state produces emission of a blue light [17]. In the absence of the green fluorescent 
protein the blue light is observed however in the presence of GFP green fluorescence is observed 
such as in Aequorea victoria [18]. No evidence of a binding complex between aequorin and GFP 
have been observed however a radiation less energy transfer occurs from the apoaequorin-




Francesco Moccia, Alessandro Bertoli, M. Catia Sorgato. 
Figure 2.2 Aequorin- Coelenterazine Mechanism. The figure above illustrates aequorin binding 
to coelenterazine and calcium generating coelenteramide and light. Blue light in the absence of 
GFP or green light in the presence of GFP. 
  
2.2.1 Green Fluorescent Protein Discovery 
The reporting of luminescence in jelly fish dates back to 50 A.D. by Pliny the Elder [20] where 
glowing slime of Pulmo marinus was described. Support for this observation followed with the 
reporting of yellow-green fluorescent masses located in the marginal canal of Aequorea [3]. 
Fluorescence was described as lasting 0.3-1.5 seconds with intensity reaching a maximum in less 
than a second. In addition to response to stimuli the study examined location of Aequorea’s 
fluorescence sighting that luminescence is an intracellular process. Critical thinking and 
experimentation, six years after the initial reporting of the fluorescence resulted in extraction and 
purification of the protein responsible for Aequorea fluorescence [2]. In addition to isolation of 
the primary photoprotein a secondary protein was isolated in trace amounts. This secondary 
protein exhibited green fluorescence and was initially termed green protein before receiving the 
permeant name of green fluorescent protein seven years after its isolation [7].               
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2.2.2 Green Fluorescent Protein Structure  
      
Composed of 238 amino acids (27KDa) [21] the green fluorescent protein is made up of 11 β 
strands aligned as a β-barrel with a single α-helix running diagonally through the center. 
Physically the β-barrel has a diameter of ~30A and a length of about 40A with small sections of 
α-helices forming caps on the ends of the barrel [22]. The nearly symmetrical cylinder serves as 
a protective unit for the fluorophore often giving rise to the moniker “light in a can”. 
Investigations have indicated that GFP resistance to heat, pH, proteases, and denaturants can be 
attributed to the compaction of the β-barrel [23]. The architectural skeleton of GFP shows a 
compact domain where the strands comprising the β-sheet are tightly fitted, in conjunction with 
the α-helix lids and loops GFP’s casing gives rise to several significant characteristics and an 
intriguing micro-environment.  
 
         Photo courtesy of Carl Zeiss Microscopy 
Figure 2.3 Structure of GFP. The above illustration shows the β-barrel of GFP with the 




2.3  Synthesis of GFP Chromophore 
 
The paramount feature of GFP, its chromophore resides near the geometric center of the compact 
cylindrical protein along the α-helix. The fluorophore is derived from peptides of the proteins 
own backbone structure. Generated from a triplet of amino acids Ser-65, Tyr-66, Gly-67 the 
driving force for chromophore formation is the stability acquired from the folding of the protein 
[1]. Once the protein advances to its near mature conformation the chromophore initiation 
process is set in motion by an approximately 80o bend within the tripeptide sequence [24]. The 
consequence of this bend disposes of a series of hydrogen bonds involving several main chains, 
now allowing for the repositioning of main chain residues near reactive sites. The widely 
accepted mechanism for the occurrence of this autocatalytic post translational multistep process 
was proposed by Tsien [25,26]. During the first step of the conjugation reaction, the amide 
nitrogen of Gly-67 attacks the carbonyl carbon of Ser-65 to promote internal cyclization. 
Cyclization is followed by dehydration to form an imidazolin-5-one intermediate [25]. Finally, 
during the rate determining step, molecular oxygen catalyzes dehydrogenation along the Cα–Cβ 
bond of Tyr-66 to form the fully conjugated ring structure yielding the 4-(p-
hydroxybenzylidene)-imidazolidin-5-one or p-HBI chromophore. Though the multi-step process 
depends on molecular oxygen the protein backbone cyclization can occur under anaerobic 
conditions indicating that the proteins local environment assist in p-HBI chromophore formation.  
The environment around the chromophore contains both apolar and polar amino acid side chains 
in addition to water molecules forming a hydrogen bonding network [19]. The residues within 
the surrounding pocket provide a scaffold for functional group catalysis specifically Arg-96 and 
Gln-222. Wachter proposed that both Arg-96 and Glu-222 residues are directly implicated in the 
cyclization and oxidation reactions [27]. Arginine-96 is believed to play a role through its ability 
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to hydrogen bond with carbonyl oxygen of Ser-65 thereby increasing the electrophilicity of the 
carbonyl carbon and promoting nucleophilic attack from Gly-67 [28]. Glutamic acid 222 is 
postulated to function as a base via carboxylate, this proton abstraction occurs from the α-carbon 
of Tyr-66 during the oxidation process [29]. In addition, Barondeau proposed that Arg-96 
together with Tyr-66 promotes α-enolate intermediate formation prior to oxidation reaction [30]. 
Various mutagenesis suggests that the Gly-67 is required for fluorophore formation [21, 31] 
however central tyrosine can be replaced by any aromatic containing residue and still yield 
fluorescent protein [32]. The protein’s local environment not only plays an assistive role in 
chromophore formation it also plays a pivotal role in the chromophores orientation. Existing in a 
cis-configuration causes the conjugated rings to assume a nearly co-planar orientation and the p-
HBI chromophore is held in rigid form by an extensive hydrogen bonding network. This 
hydrogen bonding network composed of neighboring amino acid residues prevents twisting or 
tilting of the chromophore while in the first electronic excited state [21]. Studies have suggested 
that in the absence of constraint by the proteins environment rapid dispersal of the excited state 
energy would occur as thermal or rotational energy resulting in a non-radiative decay to the 
ground state [33]. 
             
Scheme 2.4 Autocatalytic Formation of GFP-Chromophore. The above scheme illustrates the 
biosynthetic pathway of the GFP chromophore 
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2.4  GFP Photochemical Properties 
 
The innate relationship between the protein architecture and its chromophore formation has 
several translations exhibited in the proteins photochemical behavior. Wild type GFP exhibits 
two absorptions, a major peak at 398 nm and a minor shoulder at 475 nm with the different peaks 
being attributed to changes in protonation of the chromophore [33]. GFP’s chromophore can 
exists in two ionization states a neutral and anionic form. Although separate ionization states are 
responsible for two absorption frequencies, both exhibit approximately the same emission 
spectra frequency. Excitation at the major absorption frequency (neutral form) results in an 
emission at 508 nm while excitation at the latter (anionic form) yields a maximum of 503 nm 
[33]. GFP single emission is the resultant of a common electronic exited state of the fluorophore. 
Upon excitation the neutral ionization state goes to near zero becoming a strong acid this is only 
achievable by proton transfer through a pre-organized hydrogen bonding network. This excited 
state proton transfer (ESPT), which has been investigated in studies rapidly generates the excited 
state anion which emits green light [34-38].       
Mutagenesis studies have been employed to explore the effect of the local protein environment 
on the photochemical properties of GFP. Studies have demonstrated that mutations within the 
regions adjacent to the fluorophore can potentially lead to significant wavelength shifts however 
the majority result in loss of fluorescence [22]. The critical nature of Gly-67 for chromophore 
formation safe-guards this residue from mutation nonetheless mutations in tyrosine and serine 
have been investigated. Mutation of central tyrosine to phenylalanine or histidine results in a 
band shift but predominately yields a significant loss in intensity [31]. Intriguingly the mutation 
of serine to threonine results in an increase in fluorescence intensity [26,40]. The proposed 
explanation for the increase in intensity is a reduction in collisional quenching in the excited 
16 
 
state. This reduction is derived from the interactions of better packing within the interior of the 
protein because of the inclusion of the methyl moiety from threonine substitution [22]. Increased 
packing provides less exposure to the fluorophore providing a possible explanation as to reports 
that mutated serine to threonine or enhanced GFP (eGFP) is more resistant to photo bleaching 
than the wild type species [25].  
Overall the photo properties of GFP can be modulated by its local environment given rise to 
GFP’s increasing utility as a cellular probe.  
 2.5  Fluorescent Proteins  
 
Insight into the mechanism of the GFP chromophore formation and the role of surrounding 
amino acid residues assisted in the uncovering of other fluorescent protein (FP) GFP variants. 
Understood to be divided into seven spectral divisions based upon the emission maxima GFP 
variants are categorized as the following: blue fluorescent protein (BFP), cyan(CFP), yellow 
(YFP), orange (OFP), red (RFP) and far-red (FRFP). The p-HBI chromophore or variation of 
exist in all naturally occurring FP’s, however several factors determine fluorescent characteristic. 
Diversity in spectral profile is achieved by direct chemical modification of the p-HBI, via 
mutations to the residues involved in chromophore formation or residues in the protein 
microenvironment. Mutations in the central Tyr-66 in GFP gives birth to two distinctive variants 
BFP and CFP. Introduction of a histidine residue at Tyr-66 results in the formation of an 
imidazole ring during chromophore formation as opposed to a phenol moiety which 
correspondingly emits in the blue range. Substitution of identical Tyr-66 to tryptophan leads to 
the formation of an indole in the chromophore resulting in cyan fluorescence. Additional GFP 
variant subfamilies such as orange and red fluorescent proteins utilize the p-HBI chromophore as 
an intermediate where subsequent catalysis forms linkage with the polypeptide back bone and 
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extends conjugation.  Mutations in the protein local environment also give rise to GFP variants 
through associative interactions. The mutation of threonine 203 to tyrosine results in π-π stacking 
interactions between the residue and the phenolate ion in the chromophore. This interaction thus 
stabilizes the dipole moment of the chromophore resulting in yellow emissions which 
consequently turns out to be the brightest of the FP families [40]. The mutations and affiliated 
fluorescent protein emissions are displayed in figure 2.5, the available variety of colored proteins 
increases the utility within cellular applications.       
 
Pakhomov,A. Chemistry & Biology,2008,15,755-764. 
Figure 2.5. Color Variants of Fluorescent Proteins. The above scheme illustrates the diversity in 
colors that arise from modifications to GFP chromophore.   
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3.1  Nuclear Receptors Overview 
 
Essential in a series of physiological and biological process nuclear receptors are ligand 
regulated transcription factors. Superfamily of nuclear receptors serve as on/off switches with the 
ability to modulate target gene transcription. These “molecular switches” after ligand binding 
initiate specific genetic sequences that regulate extracellular environments from intracellular 
communication. Nuclear receptors reside in a wide variety of tissue and organ distribution within 
the body with diverse receptors being expressed at different levels in different organelles. At a 
subcellular level some nuclear receptors translocate, initially residing in the cytoplasm in an 
unbound state, upon ligand binding the receptor permeates the nucleus. Except for the estrogen 
receptors that exist in both bound and unbound state in the nucleus, nuclear receptors are 
cytosolic. The research that encompasses nuclear receptors has developed into a broad spectrum 
of topics ranging from structural & functional analysis, molecular mechanism and ligand 
modulation.        
The first nuclear receptor was identified biochemically in the 1960’s (Jensen), its identification 
subsequently led to the first cloning of a nuclear receptor, glucocorticoid receptor (Evans) [1].  
Initially isolated and identified via laborious laboratory techniques, the knowledge that nuclear 
receptors could be isolated without the ligand increased the rate of identification [2]. Confirmed 
in 2001 via the human genome sequence the 48 nuclear receptor genes located in mammalians 
are the complete nuclear receptor genome [3]. Among the 48 identified nuclear receptors only 24 
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have either endogenous ligands or identified ligands, those receptors lacking known ligands are 
termed orphan receptors [4]. More commonly the superfamily of nuclear receptors has been 
divided into subfamilies predicated upon the class of ligand they are regulated by. The bulk of 
the nuclear receptor superfamily is predominately regulated by small hydrophobic molecules 
from diverse classifications including steroids, bile acids, and hormones. Incorporated in the 
subfamilies are the steroid receptors, retinoid (RXR heterodimer) receptors and xenobiotic 
receptors. The subfamily of steroidal receptors composes the glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), progesterone receptor (PR), androgen receptor (AR), and the 
estrogen receptor (ER). This set of receptors of which many have isomeric forms are activated by 
steroidal ligands both synthetic and natural. The next subfamily commonly activated by fatty 
acids, oxysterols, bile acids, vitamins and hormones are the retinoidal or RXR heterodimer 
receptors. This category of receptor houses the peroxisome proliferators activated (PPAR), liver 
x receptor (LXR), farnesoid x receptor (FXR) and the retinoid x receptor (RXR). Though divided 
into categories and sub-divisions and housing cellular controls for various processes these 
modulators harbor inherent features. 
 
3.2  Nuclear Receptor Structure (Regions and Domains) 
 
A unifying feature of the nuclear receptor superfamily is that each receptor consists of an 
assembly of functional modules. Nuclear receptors are composed of several characteristic 
domains commonly denoted as A-F regions [5,6] as illustrated in Fig. 3.1. The A/B region also 
noted as the N-terminal domain houses an independent-ligand activation transcription factor 
(AF-1).  This region displays a large degree of variance not only among nuclear receptors but 
also within isoforms. In fact, the A/B region is one of the least conserved among receptors, 
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however numerous studies indicate a commonality in the ability to regulate via phosphorylation 
[7-9]. To date no three-dimensional structure has been solved for this region. Residing within the 
C-region is the DNA binding domain (DBD). The DBD one of two focal points of the nuclear 
receptor is connected to the ligand binding domain (LBD) by a hinge designated as region D. 
The E region houses the activation factor 2 (AF-2) as well as the LBD, the hallmark of the 
nuclear receptor. Lastly the F region is composed of the C-terminal domain which is highly 
variable in sequence between various receptors. The merger of these functional modules creates 









Figure 3.1 Nuclear receptors regions-domains. Structurally nuclear receptor shares 5 common 
domains illustrated above are the domains with defining characteristics.  
 
 
3.2.1 Activation transcription factor (AF-1)  
AF-1 varies in length and sequence between receptor groups and families. It is recognized by 
various accessory proteins termed promoters [10] however demonstrates specificity for cell, 
DBD and promoter interaction.  
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 3.2.2 DNA binding domain 
The DNA binding domain is one of two extensively studied focal points within the nuclear 
receptor. The predominate role of the DBD is to recognize and bind to specific DNA sequences 
termed hormone response elements (HRE). These short sequences of DNA exist within the 
promoter of the gene and allow for regulation of transcription [5]. The DNA binding domain is 
highly conserved among receptors being observed in all nuclear receptors except for two DAX1 
and SHP which both lack the ability to directly associate with DNA [11]. Typically composed of 
between 70-80 amino acids the pivotal DBD is structurally known to be helix-loop-helix with the 
two alpha helices packed perpendicular to the center of the polypeptides [12, 6]. The DBD 
possess two zinc ions chelated by cysteine (histidine residues are common as well) residues 
commonly referred to as zinc fingers at the start of each helix. Within and between these 2 
cysteine rich zinc fingers are several sequence elements termed P, D, T, and A boxes [7]. These 
elements play crucial roles in response element specificity, dimerization interface and interaction 
with DNA backbone. A modification of amino acid sequences within this region, specifically the 
P-box can result in interconversion of nuclear receptor response element recognition [11].  
3.2.3 Ligand binding domain 
 
The LBD or ligand binding domain is the staple of the nuclear receptor; located within the E-
region which additionally houses a ligand-dependent activation factor termed AF-2 [13]. The 
LBD of nuclear receptors demonstrate a large amount of conservation between receptors and 
families and still maintains enough divergence to remain ligand selective. Multiple crystal 
structures of this region have been solved both independent and in the presence of agonist, 
antagonist and peptides. The LBD structurally consist of 11-13 helices arranged in three layers 
[14]. Within these helices exist a ligand binding pocket (LBP) which is guarded by a twelfth 
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helix [13]. This helix twelve (H12) forms a lid over the LBP and contains residues crucial for the 
function of AF-2, co-activator or co-repressor recruitment [13,15].  Structural insight of the LBP 
has operated as the centerpiece for nuclear receptor modulation research. Broadly the LBP can be 
characterized as a cavity highlighted by nonpolar amino acid residues while possessing few polar 
residues. Structurally the LBP is divergent across receptors and within receptor families varying 
in shape, size, volume and residues. The disparity within the LBP provides the distinguishing 
feature that allows differentiation between ligands.   
3.2.4 Activation transcription factor (AF-2)     
 
AF-2 is a well conserved ligand dependent activation factor located on the surface of the LBD 
[16]. The ability of AF-2 to play a role in co-activator or co-repressor relationships with the 
receptor has caused this factor to garner a significant amount of attention for nuclear receptor 
modulation and signaling.     
    
3.3 Nuclear Receptor Domain Function 
 
3.3.1 Activation Transcription Factor-1 (AF-1) 
 
This ligand-independent activation factor regulates gene transcription in co-operation with AF-2 
to promote maximal gene expression. 
3.3.2 DNA Binding Domain 
The DBD serves to read the HRE and bind selective response elements upstream of the target 
gene predicated on the class of receptor, therefore receptors can be distinguished by specific 
DNA sequences. The DBD also dictates dimerization, receptors can function as homodimers, 
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heterodimers or monomers. Several advantages to the binding site arise from dimerization 
including affinity, specificity and diversity.   
3.3.3 Hormone Response Elements 
The hormone response elements reside in the promoter gene and binds to the hormone receptor 
via the DBD this serves to allow transcription of genes under the influence of the hormone to be 
regulated by means of the receptor. 
3.3.4 Hinge 
The hinge plays an important role in conformational changes by not only connecting the DBD to 
the LBD but in a manner as to provide flexibility. The importance of this act is to ensure 
conformational changes can occur without the presence of steric hindrance. In addition, the hinge 
also serves to house the nuclear localization signal (NLS) which facilitates the receptors uptake 
into the nucleus.  
3.3.5 Ligand Binding Domain 
While the ligand binding domain contributes to the dimerization interface shared by the DBD, it 
predominately houses several important modules critical for ligand mediated response; of which 
none more important than the ligand binding pocket. The ligand binding pocket serves to bind 
and transcribe the cryptic information integrated within the ligand while providing protection 
from the external cellular environment in a solvent free surrounding.  
3.3.6 Activation Transcription Factor-2 (AF-2) 
The primary role of AF-2 is the recruitment or release of co-activators or co-repressors 
respectively. The course of action embarked upon by AF-2 is a consequence of the presence of a 
ligand thus making the transcription factor ligand dependent.   
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3.4 Nuclear Receptor Ligands 
Nuclear receptor ligands both natural and synthetic are diverse in structure and function across 
the superfamily of receptors as illustrated in Fig. 3.2. The very nature of the ligands ability to 
bind within the nuclear receptor demands that ligands are defined by certain criteria. Typically, 
small and mainly hydrophobic molecules many of which contain polar functionality affixed at 
the ends of the molecule to form hydrogen bonds or electrostatic interactions to increase 
stability. Irrespective of the class of nuclear receptor, ligands can be grouped into two headings 
natural or synthetic. Natural ligands are those derived from biosynthetic pathways (lipids, PG’s, 
hormones) including derivatives or metabolites of the products biosynthetic pathway. In 
opposition synthetic ligands are lab engineered, often using endogenous ligands as a basis for 
design or starting point. Whether natural or synthetic, ligands predominately are divided into 
classification predicated upon the response generated from the receptor.  
The wide distribution of nuclear receptors within the body makes ligands that are both receptor 
and tissue selective often referred to as selective nuclear receptor modulators of increased 
interest. Ultimately the observed physiological response is a direct result of the encoded message 
transcribed by the ligand. Ligands are determined to be agonist or antagonist both of which 
headline several sub classifications as descriptors. 
3.4.1. Agonist 
Agonist with respect to nuclear receptors by description are compounds that bind and 
allosterically promote dissociation of co-repressor proteins and recruitment of co-activator 




Figure 3.2 Natural and synthetic ligands for various nuclear receptors. Diverse agonistic ligands 
for various nuclear receptors are shown both natural ligands and synthetic. 
 
Under the general classification of agonist are additional titles offering more refinement. Agonist 
ligands can elicit maximal response (full agonist), response greater than that of the endogenous 
ligand (super agonist) or response lower than that of maximal (partial agonist). Computational 
calculations have demonstrated many nuclear receptor agonist ligands fall within a molecular 
volume of 250-350 A3[16]. In general molecules capable of promoting agonistic behavior within 
the receptor are predicted to be hydrophobic, rigid in skeleton and possessing polar groups on the 
ends of the molecule. In addition to natural agonist, synthetic agonist for nuclear receptors exist 
and have done very well commercially such as Targretin (Bexarotene) an RXR agonist approved 




Antagonist bind to the nuclear receptor within the ligand binding domain but promote 
detainment of co-repressor proteins thus suspending the transcription pathway. Ligands that can 
be classified as antagonist upon bonding can further be described as affinity reliant for retention 
(competitive antagonist), affecting the magnitude of the response capability (noncompetitive 
antagonist), allosterically influenced by a pre-exposed agonist (uncompetitive antagonist) or 
possessing zero efficacy for activation (silent antagonist). 
Generally, antagonist have the skeleton of the agonist however the antagonist possesses a larger 
scaffold extending from the molecule commonly arising from the center of the skeleton with the 
intent to disrupt helix packing (Ex: Diethylstilbestrol vs Tamoxifen shown in Fig. 3.3). 
Analogous to agonist, synthetic antagonist compounds have achieved a considerable amount of 
commercial success with the most notable being Tamoxifen used in the treatment of breast 
cancer.  
 
Figure 3.3 Shared Skeleton of agonist conversion to antagonist. Commonly the skeleton for 




3.5 Mechanism of Ligand Mediated Receptors 
 
The turn on of gene transcription via nuclear receptor modulation involves a sequence of events 
composed of complex association and auxiliary co-factors. The receptor resides in two states an 
inactive state (apo) which exist in the absence of a ligand or an active state (holo) which is ligand 
bound and thus commences a cascade. For mechanistic action of the nuclear receptor to occur, 
the receptor must be able to bind to a ligand then recognize HRE near or in the target gene and 
finally alter transcription rate of the target promoter. It is only once the ability to satisfy these 
criteria can be meet that the mediated mechanism can begin. 
The binding of the ligand is the first pivotal event that must occur for mediated transcription to 
occur. Once bound the ligand is completely engulfed within the LBP and contacts with amino 
acid residues within this highly hydrophobic core are formed with the ligand. A ligand induced 
conformation change also occurs of the LBD, repositioning helix 12 this alteration 
predominately exists in steroid receptors. The new orientation of helix 12 forms a seal over the 
LBP and is direct consequence of the bound ligand. The movement of helix 12 has been depicted 
in two models the mouse trap model and the dynamic stabilization model. This induced 
conformational change generates a transcriptionally competent AF-2 and allows for the 
continuation of the mechanistic scheme.  
Association of coregulatory complexes with the receptor is the next crucial occurrence, ligand 
binding induces an allosteric effect in AF-2 signaling recruitment of auxiliary proteins. 
Coregulatory proteins serve one of two purposes either promotion of activation (co-activators) or 
repression (co-repression) each occurring in response to the presence or absence of a ligand. In 
the presence of an activating ligand (agonist) co-activators such as steroid receptor coactivator 
(SRC-1) are recruited. Residing within this peptide is a LxxLL ( L=leucine, x = any amino acid 
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residue) motif otherwise known as a nuclear box that interacts directly with the LBD of the 
receptor. This coactivator-receptor interaction occurs within a hydrophobic groove involving 
residues in helices 3 and 12, lysine and glutamic acid respectively hydrogen bonding with 
carbonyls in the backbone of the nuclear receptor box [7]. These co-activator, serve to bind 
acetylated histones thus weakening histone-DNA interaction resultant in relaxed chromatin from 
the promoter gene. After this exchange of co-regulators, RNA polymerase II is recruited and 
mRNA transcription is initiated. In the absence of a ligand co-repressors are bound, that have yet 
to undergo disassociation from the receptor the most commonly of which have been studied are 
nuclear corepressor (NCoR) and silencing mediator for retinoid and thyroid receptor (SMRT). 
Similar peptide motifs found in the nuclear receptor boxes are also located within the 
corepressors however interactions do not involve helix 12. These corepressors serve to recruit 
histone deacetylase (HDAC) which results in condensation of chromatin above the promoter 
gene ultimately repressing transcription. Subsequently binding of an antagonist involves 
retention of corepressors, where upon conformational change places helix 12 in an orientation 
that prevents recruitment of co-activators.          
The ligand-ligand binding domain relationship can be viewed as input-output system wherein the 
ligand (input) binds within the LBD, induces allosteric changes at the receptors surfaces and the 
information encoded within the small molecule is communicated to the intracellular environment 
(output) [15]. The margin for error within the signaling communication process causes nuclear 
receptors to be implicated in a vast amount of diseases. 
3.5.1. Apo 
 
Not many crystal structures have been generated for unliganded receptor ligand binding domain 
since the addition of the ligand generally adds stability. Under the guides of the mouse trap 
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model when a receptor is void of a ligand helix 12 is far away from the body of the LBD. 
Contrary to the mouse trap model, the dynamic stabilization model indicates that even in the 
absence of a ligand helix 12 is close to the body of the receptor. The dynamic stabilization model 
even states that in some cases helix12 proximity is so close that it forms a lid over the LBD 
during an inactive state, however the helix is not fixed and labeled as more molten. While it 
appears, disunity may arise with respect to the positioning of helix 12 during the Apo state 
consensus is the unliganded receptor allows more fluidity in the LBD and less restriction to the 
surrounding helices.    
3.5.2. Halo 
 
Much of crystal structures solved for nuclear receptor ligand binding domains exist within the 
Halo or bound state. As described with the mouse trap model once in the bonded state helix 12 
moves proximal to the ligand however this model has only proven true for two receptors RAR 
and RXR LBD [17]. The dynamic stabilization model describes the introduction of ligand as 
lowering folding energy globally for the receptor. This thereby reduces conformational dynamics 
and fixies helix 12 in a stable conformation. Under the scope of the dynamic stabilization model 
receptors that are constitutively active can be unliganded and stable on account of helix 12 
already having the most stable conformation.   
 
 
3.6 Nuclear Receptors Role in Diseases 
 
Nuclear Receptors have been linked in a variety of roles to various diseases [18]. The 
correlational between receptor under expression and occurrence of disease has been implied with 
vitamin D receptor and its link to type I diabetes mellitus [19], estrogen receptor β and its link to 
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colon and prostate cancers [20]. Oppositely overexpression has been observed with estrogen 
receptor α in mammary gland estrogen receptor positive tumors [21]. In addition to varying 
expression levels linking diseases to nuclear receptors, process regulation controlled by the 
receptor can trigger responses that aid in the treatment of diseases one such example is regulation 
of apolipoprotein E (ApoE) and its lipid transporters via liver X receptor (LXR) aids in amyloid 
β clearance in the treatment of Alzheimers disease [22]. Several studies have shown that 
deregulation of nuclear receptors can play pivotal roles in specific human diseases [18,19]. 
Nuclear receptors including the estrogen receptor (ER), peroxisome proliferator-activated 
receptor gamma (PPARγ) and retinoid x receptor (RXRα) have emerged to the forefront of 
investigation for implications in diseases ranging from neurological, metabolic and cancers. 
3.6.1 Estrogen Receptor 
 
The role of estrogen receptor in human disease received wide spread attention with its link to 
breast cancer, however the receptor has been implicated in other types of cancers. Associated 
with ovarian, colon and suggestive in prostate cancers estrogen receptor is believed to play 
varying roles in different types of cancers. In some cancers (ovarian) high level of estrogen 
expression is a disservice with cancer cell growth supported by the presence of an agonist. In 
other forms of cancer, a more protective role is initiated where agonist is needed due to low 
expression levels of estrogen receptor.     
In addition to cancers estrogen receptor has been linked to neurological as well as cardiovascular 
diseases. Evidence has suggested within cardiovascular disease that estrogen receptors have both 
a direct and indirect role lowering the risk for coronary disease. One of the direct role estrogen 
receptor families play is via its ability to be stimulated to trigger the rapid release of nitric oxide 
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within cardiovascular smooth muscle. The significance of this release is that nitric oxide relaxes 
vascular smooth muscle which in turn inhibits platelet aggregation.   
3.6.2 Peroxisome Proliferator-Activated Receptor gamma 
 
The peroxisome proliferator-activated receptor and its sub-types have demonstrated the ability to 
mediate inflammatory responses via ligand regulation [23,24]. Neurodegenerative diseases all 
induce potent inflammation in the brain as the immune systems response to disease-initiated 
agitation. Control over inflammatory response can be governed by a diverse cluster of immune 
mediators including pro-inflammatory cytokines. In addition to inflammation several neuro-
diseases such as Huntington and Alzheimer show high levels of protein (amyloid) build up. 
Other degenerative diseases, Parkinson for example show reduced levels of specific co-activators 
mainly PCG-1α (principal cofactor). PPAR and in addition to other families of receptors are 
highly expressed in the brain and all cell types in the central nervous system. A significant 
number of studies have exemplified the ability of PPAR agonist to suppress cerebral 
inflammation and reduction of amyloid levels in mice with Alzheimer’s. In addition to 
inflammatory regulation the PPARγ subtype action is bound to expression of PCG-1α, therefore 
binding of agonist stimulate expression. PCG-1α deficiencies have also been shown to be culprit 
in other mechanistic pathways such as insulin sensitivity, energy production and neuronal 
viability. Metabolic diseases including but not limited to obesity, type II diabetes and 
hypertension have all been linked to cellular factors that are regulated by nuclear receptors [25]. 
3.7 Nuclear Receptor Role as Pharmaceutical Targets 
Drug design and discovery has chiefly been fueled by two systematic approaches: phenotypic 
screening and target-based design, with the latter affirming its position by the end of the mid-20th 
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century. In target-based approach, a selected biochemical mechanism is proposed to be 
implicated in a disease(s) and modulation of biochemical factors within these mechanisms serve 
as targets for drug discovery. Classical target-based approach centers around deconstructing the 
biochemical pathways to develop a strengthened mechanistic derived targeted approach. The 
benefit of this type of approach is often the biochemical factor (target) can be incorporated in 
screening thereby increasing efficacy of lead discovery process while minimizing discovery time 
[26]. Additionally, target inclusion in screening provides the opportunity to gain insight about 
the interaction between the ligand and the biochemical factor of interest. Critical information can 
be gained through understanding these relationships such as hydrophobicity, donor-acceptor 
roles and ligand restrictions, ultimately leading to more rationale screening. Target based derived 
approaches resulted in Food and Drug Administration (FDA) approval of 78 out of 113 first in 
class drugs (1999-2008) [27] facilitating the emergence of target-based drug discovery approach 
as an applicable tool for new drug identification.  
Nuclear receptors are a class of proteins that have often been subjected to target-based approach 
for the discovery of potential new ligands for these receptors. As ligand activated transcription 
factors, these receptors play an integral part in several metabolic and developmental processes; 
thus, have been implicated in several diseases, ranging from atherosclerosis to cancer.  To date 
there are 48 human nuclear receptors that have been identified, each of which can regulate 
expression of genes under its control thus linking receptors to key physiological responses [3]. 
The potential for error within the ligand-initiated communication between the nuclear receptor 




Modulation or inhibition of these biological pathways to turn on/off key physiological responses 
for treatment of disease makes nuclear receptors “pharmaceutically significant”. 
Nuclear receptors ability to act in concert with a host of cellular factors in response to 
introduction by a ligand provides a stage for their role in drug discovery. Nuclear receptor 
signaling targets accounted for 107 new FDA approved drugs by the end of 2013, making them 
the third most targeted and fastest-growing class of protein targets, with almost two small 
molecules approved per year for these receptors [28]. The growth of interest in ligand generation 
has not gone unnoticed by the pharmaceutical industry with 33% of nuclear receptors being 
targets [29] estimates suggest that nuclear receptor ligands constitute 10-20 % of worldwide 
pharmaceuticals [30]. Not only have nuclear receptor ligands claimed stake in the 
pharmaceutical industry but have exceled, as of 2003 the top 200 most prescribed drugs included 
34 that targeted nuclear receptors [31]. Pharmaceutical industry involvement in receptor 
therapeutic ligand development has resulted in [32] several commercially successful compounds. 
As illustrated in figure 3.4 ligands such as Tamoxifen for treating breast cancer via the estrogen 
receptor, Flovent, a corticosteroid used to treat asthma by selectively targeting the glucocorticoid 
receptor, Casodex, an antagonist for the androgen receptor in the treatment of prostate cancer and 
Avandia, the antidiabetic drug which binds the peroxisome proliferator-activated receptor 
successfully impacted pharmaceutical sales. A developed understanding of how ligands turn on 




Figure 3.4 Commercially available nuclear receptor ligands. The above ligands are part of the 
worldwide pharmaceutical market with large sales in the treatment of various diseases and 
conditions. 
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SYNTHESIS OF GFP CHROMOPHORE INSPIRIED LIGANDS AS 
ESTROGEN RECEPTOR ALPHA AGONIST 
 
4.1 Estrogen Receptor 
 
Estrogen receptor (ER) resides under the classification of steroidal nuclear receptors and exist as 
two isoforms in mammals, estrogen receptor α (ERα) and estrogen receptor β (ERβ) [1]. 
Discovered in the 1960's and cloned in the 1980's it was not until after the discovery of a second 
subtype that the original receptor was renamed estrogen receptor α [2,3]. Like most nuclear 
receptors ERα and ERβ are ligand regulated, with 17β-estradiol (E2) being its endogenous 
ligand. It is worth mentioning that receptors similar in nature and function of the estrogen 
receptor have been discovered termed estrogen related receptors (ERR) however they do not 
bind estradiol (E2) and no known endogenous ligand exist. [4, 5]. Due to its subcellular mode of 
action ER is labeled as a Type 1 receptor. In the absence of a ligand ER is cytosolic anchored by 
chaperone proteins commonly heat shock proteins (HSP). Ligand binding initiates HSP release 
followed by dimerization and translocation into the nucleus [6]. Once in the nucleus association 
with transcriptional coactivators that facilitate binding and activation of target genes occurs. [7]. 
The estrogen receptor family is among nuclear receptors that have warranted considerable 
attention.  
4.1.1 Estrogen Receptor Alpha 
 
While both estrogen receptor subtypes can be considered pharmaceutically significant ERα 
classically named NR3A1 is a vested therapeutically targeted receptor in contraception, fertility 
enhancement, hormonal therapy, and breast cancer therapies. Consisting of 595 amino acid 
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residues ERα is predominately composed of alpha helixes with less than 3% beta sheets and the 
rest being turns and loops.  
Estrogen receptor α mRNA has wide spread distribution within various sites in the body such as 
mammary gland, ovary, testes and sections on the brain [8]. As illustrated in table 4.1 expression 
can be observed in high to moderate even low levels within specific tissues and organs. In 
addition to being located within the cardiovascular and central nervous system the uterus and 
pituitary gland express ERα however only after maturity of the tissue has been reached [9] 
Table 4.1 Estrogen receptor α tissue distribution and expression levels. The above table 








4.1.2 Ligand Binding Pocket   
 
The crystal structure of ERα-LBD complexed with 17β-estradiol gave a large amount of insight 
into the relationship between the ligand binding pocket (LBP) and ligands [9, 10]. The LBP is 
formed by residues from helices 3,6,8,11,12 as well as the loop region between helix 7 and 8. 
With a volume size of 450A3, the LBP is completely partitioned from the external environment 
and generates a fairly large portion of the hydrophobic core of the LBD as shown in figure 4.1. 
Full agonistic behavior is believed to be achieved when the ligand is encapsulated into the 
hydrophobic binding pocket and H12 can seal the pocket [11, 12, 13]. The importance of 
conservation of specific residues, spatial availability and flexibility within the pocket has been 
extensively studied [13,14] with results suggestive that ligand volume (size, shape), hydrogen 
Tissue ERα Expression Level 
Reproductive (testies, ovaries) high 
Prostate, bladder and liver moderate 
Epididymis, pituitary gland, thymus low 
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bonding network and ligand molecular topology are crucial criteria for successful activation. 
Estrogen receptor α's wide distribution in human tissue and roles in many physiological systems 
links it to diseases such as osteoporosis, cardiovascular, obesity, Alzheimer, autoimmune and 
cancer (breast & ovarian) [15, 16, 17]. Thereby continuing the interest in development of ligands 
that bind ERα. 
 
Figure 4.1 Estrogen Receptor α complexed with estradiol. Secondary structure of ERα with 
estradiol (E2 in green), inset: ligand binding pocket residues complexed with E2 exemplifying 
the depth of pocket in the protein.   
 
 4.1.3 Ligands 
Successful modulation of ERα has been demonstrated across a broad class of ligands including 
both steroidal and non-steroidal. A comprehensive investigation into the two categories of 
ligands demonstrate agonist and antagonist for ERα that are synthetic, non-synthetic and 
secondary metabolites as illustrated in figure 4.2 [18]. ERα ligands can be divided into several 
classes including natural steroidal, synthetic non-steroidal and plant secondary metabolites [19]. 
The ability of ERα to bind such a diverse set of compounds would suggest promiscuity in 
binding, however despite the origins of these ligands in relation to diversity in species, there are 
commonalties amongst the diversity. Several studies have been published investigating common 
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core features of estrogen receptor ligands. Of those studies Katzenellenbogen et al. identified a 
generic model estrogen receptor pharmacophore [14] as illustrated in figure 4.3.  
 
Figure 4.2 Known estrogen receptor ligands. Identified estrogen receptor ligands with 
requirements highlighted (blue & red) in relation to established Katzenellenbogen ERα 
pharmacophore. 
 
Figure 4.3 Estrogen receptor pharmacophore. The above figure illustrates the estrogen receptor 
non-selective pharmacophore established by Katzenellenbogen with distinguishing features 
highlighted in red and blue corresponding to figure 4.2.  
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Lengthy studies into known estrogen receptor modulators and their potential interactions within 
the receptor ligand binding pocket enabled Katzenellenbogen to unravel features that are 
exchangeable from those that are indispensable. Reviews have been compiled in which various 
categories of synthetic compounds and natural product analogs support this model [20, 21.]. 
While estradiol, ERα endogenous ligand skeleton is composed of an ABCD ring system, this 
proposed pharmacophore embraces estrogen receptor modulators that only contain ACD ring 
systems.  The commercial success of ERα modulators has exacerbated the development of 
additional ligands for physiological perturbation. 
 
4.2 Estrogen Receptor Ligand Design Rationale 
 
Guided by investigation into the photo physics of the green fluorescent protein chromophore our 
lab extensively studied the arylmethyleneimidazolone (AMI) core [22-26]. Generated via a post 
translational autocatalytic cyclization followed by autoxidation involving specific residues 
within the protein this core is composed of key features exemplified in known estrogen receptor 
modulators. In addition to notable features, the AMI skeleton is amenable to being reminiscent of 
the ACD ring scaffold proposed by Katzenellenbogen [14]. Estrogen receptor’s endogenous 
ligand estradiol possess a ABCD ring structure however an established precedence exists for 
utilizing a ACD ring system. Also termed B-ring seco-steroids and B ring seco-estradiols initial 
reports of ACD systems surfaced in 1959 by Novello [27]. Early estrogenic activity was studied 
by Bindra, Neyyarapally and co-workers in ACD systems [28, 29]. Katzenellenbogen reported of 
ACD systems inspired by genistein with high potency and isotype selectivity [30]. The ACD 
system boast principal advantages over the classical ABCD ring system primarily the easy of 
functionalization in the A and D systems. The established foundation and success of the ACD 
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system with binding and selectivity in the estrogen receptor prompts discovery for other sources 
of ACD system inspiration.        
 Visual inspection of known estrogen receptor α ligands and AMI analogues previously 
synthesized by Baldridge [31] display significant structural commonalities that can be viewed as 





Figure 4.4 Rationale for development of GFP inspired arylenemethylene imidazolone analogue. 
The above figure highlights the initial GFP core (green) as being amendable to structural changes 
to satisfy ER pharmacophore requirements colored blue and red. Support is also provided for the 
use of ACD ring structure with pyrazine and enterolactone example.   
 
Overall the usage of AMI chromophores as ligands for estrogen receptor α activation highlights 
several advantageous points including providing a skeleton pre-equipped with key features for 
estrogen receptor activation, a tunable scaffold that may lead to enhanced selectivity here-go 
minimizing undesired side effects while maintaining facile generation of synthetic analogues. 
Herein we report a novel class of ERα agonist designed from GFP’s chromophore core structure. 
Simple benzamides have been reported by Caldarelli [32] to demonstrate agonist behavior 
however to our knowledge this is the first example of GFP-derived class of agonist. Using 
chemical complementation in yeast and luciferase assay in mammalian cells a library of 
compounds was screened for agonistic behavior. Additional AMI's were designed and 
synthesized based on results and a structure activity relationship (SAR) developed for top 
activators. 
Previously defined SAR through the work of Katzenellenbogen and others in designing 
acceptable ligands for estrogen receptor mandates that consideration be given to certain criteria. 
With these benchmarks in mind ligands were designed to adhere to the following guidelines: 
1) Maintaining the hydrogen bonding network as defined by the ligands relationship with 
the following residues Glutamine-353, Arginine-394 and Histidine-524. 




3) Maintain molecular topology as defined by polarity of the molecule with specific 
attention given to the scaffold or core.   
4.2.1 Hydrogen Bonding Network                                                                                  
The preservation of hydrogen bonding networks around the Gln-353, Arg-394, His-524 residues 
were shown a key contributing factor for activity of the ligand [10]. Estradiol has showcased the 
importance of this network (Figure 4.5) in several aspects.  
Figure 4.5 Ligand binding pocket of estrogen receptor α. Critical residues highlighted in yellow 
sticks establish a hydrogen bonding network with estradiol (green). Residues and estradiol 
contact are under 4A of proximity. 
Aside from contributions by possible weak polar interactions from the aromatic ring the 
hydrogen donor effect of the phenolic moiety (A-ring) with Gln-353 and Arg-394 has been 
outlined in a series of reviews [14, 33]. Likewise, the ability of histidine or tyrosine to serve as 
hydrogen donor has defined the role played by His-524 with the 17β position of estradiol [14]. 
Therefore, to design ligands compounds were generated to explore the contribution from each 
facet of the hydrogen bonding network. Compounds containing a combination of accessible 
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(CW28), capped (CW24), sterically hindered (CW25, CW27), or meta/ortho/para substituted 
(CW29, CW30, CW31, CW32) phenolic moieties were synthesized to evaluate the role of the 
relationship with Gln-353 and Arg-394. An analogue bearing no hydroxyl substituent (CW33) 
was included to serve as a control for this series of compounds.  In investigating the role of His-
524 as a hydrogen bond donor or acceptor the amide was alkylated with a secondary phenolic 
ring. Attenuations of the hydroxyl group of the newly added phenol generated ortho and para 
substituted compounds yielding CW36, CW34 respectively. In addition, CW39 was synthesized 
that methylated the secondary phenol rendering its role to hydrogen bond acceptor exclusively. It 
is important to note that the primary phenol located on the A-ring on the AMI analogues were 
held in the para position for consistency with the phenol location in estradiol’s A-ring ensuring 
that any diversity in activation was a direct result of modification of His-524 roles. 
4.2.2 Ligand Volume and Size 
 
Ligand volume (size and shape) have been linked as co-factors that contribute to modulation 
with the proper size ligand possessing the ability to induce receptor folding. Katzenellenbogen et 
al. demonstrated with a series of acyclic amides employing a homobibenzyl backbone that 
activation is not observed until a ligand of sufficient size was generated [34,35]. Literature has 
also shown that while estrogen receptor α LBP can accommodate larger ligands highly effective 
agonistic ligands have molecular volumes significantly smaller than pocket spatial availability 
including estradiol and diethylstilbestrol at 250A3 [19]. Volumetric calculations of the AMI core 
(unsubstituted) shows a molecular volume of 179.8A3, perturbations in volume are rooted in 
substituent selection therefore substituents were strategically selected as to enhance potency in 
accordance with literature while not violating the spatial threshold. Small nonpolar moieties such 
as simple alkyls, as well as polar and basic aryl substituents are implicated in enhanced potency, 
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for instance n-propyl and isopropyl, substitutions at the 11β (E2) position have been linked to 
improved binding affinities [2]. To that avail propyl and isopropyl substituents were added to 
analogues previously constructed to explore hydrogen bonding network. Analogues CW24, 
CW25, CW29, CW30, CW33 were all alkylated with n-propyl substituents were as CW27, 
CW28, CW31, CW32, were all alkylated with isopropyl substituents. Cyclic substituents such as 
cyclohexyl and cyclopentyl rings CW35 and CW38 respectively were added first to increase 
ligand size and secondly further exploration of isopropyl spatial limitations with regards to 
improving binding affinities. 
4.2.3. Molecular Topology  
 
Lastly molecular topology i.e. polar surface area seems to be influential in potency of binding 
affinities. While substitutions may attenuate molecular polarity ultimately the core or scaffold 
provides an inherent contributor. The incorporation of hetero-cyclic scaffolds to provoke 
estrogen receptor α modulation is not unprecedented, however studies associate the greater the 
polarity in the core a greater loss in activity possibly due to a higher desolvation penalty within 
the LBD [36]. The benzyl methyleneimidzolone is our intrinsic core however analogues were 
synthesized bearing tetralin (CW1, CW7, CW16) and napthyl (CW59, CW60) substituents 
attached to the core to reduce total molecule polarity while still generating a ligand of 




Figure 4.6 Synthesized generation I compounds. Above compounds were synthesized to explore 
criteria of estrogen receptor α ligand binding pocket residues and this class of compound. 





4.3 Synthesis of Arylmethyleneimidazolone 
 
Successful creation of an AMI library is reliant upon a synthetic methodology that allows for 
facile generation and derivatization of analogues. In addition, methodology must be amenable to 
diversification of substituents to allow for maximal exploration of the residue contacts within the 
ligand binding pocket. Dr. Baldridge generated an approach based upon adaptations to methods 
established by Bazureau that allowed for a more combinatorial route [37]. Baldridge’s approach 
envisioned the substituted arylmethyleneimidazolone (3) arising from the 2+3 cycloaddition of 
an iminoglycine (2) methyl ester and a Schiff base (1). The Schiff Base was generated by 
addition of 1.1 equivalent of primary or secondary amine in the presence of an aryl aldehyde and 
stirred overnight. In cases where both reagents were liquid reaction was run neat, when a solid 
was present methanol was used as a solvent as illustrated in figure 4.7 below.  
 
Figure 4.7 Synthesis of Arylmethyleneimidazolones.    
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Construction of the Schiff Base is the hallmark for diversity in the generation of analogues. The 
limitation of diversity that can be incorporated on the aryl ring or amide is solely contingent 
upon the availability of aryl aldehydes and amines, with a broad number of these reagents 
commercially available as well as synthetically accessible opportunities are vast. In addition to 
commercially available aldehydes, the tetralin core was generated in three steps from known 
literature procedure [38,39]. 
 
Figure 4.8 Synthesis of tetralin aldehyde 
Starting with the commercially available aliphatic diol (I) conversion to the dihalide (II), was 
carried out by addition of concentrated hydrochloric acid. The substituted aryl ring (III) was 
generated via Fridel Crafts Alkylation and after oxidation yielded the tetralin based aldehyde 
(IV) as shown in Figure 4.8. Formation of the iminoglycine methyl ester was carried out by the 
addition of potassium carbonate, methyl glycimate hydrochloride and ethyl acetimidate 
hydrochloride in ether with vigorous shaking and frequent venting. Cycloaddition was carried 
out by addition of 1.0 equivalent of iminoglycine methy ester with 1.0 equivalent of Schiff base 
and stirred overnight in methanol. Most of reactions precipitated as yellow or tan powders which 
were filtered, washed with cold methanol and dried in vacuo. Crystallization was achieved for 
several products at 00C for 2-3 days resulting in yellow to orange crystals. A smaller subset of 
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products was isolated via column chromatography using ethanol/hexane gradient. Utilization of 
this protocol facilitated synthesis of 72 GFP chromophore inspired compounds with various 
substitutions. All substituted AMI ligands were synthesized in excellent to modest yields. 




R1 R2 Ligand 
 
R1 R2 Ligand R1 R2 
CW1 tetralin n-propyl CW35 ρ-hydroxy cyclopentyl CW63 2,4-diol ρ-phenol 
CW2 tetralin n-butyl CW36 ρ-hydroxy σ-phenol CW64 2,4-diol propyl 
CW3 tetralin n-pentyl CW38 ρ-hydroxy cyclohexyl CW68 2,4-diol cyclopentyl 
CW4 tetralin n-hexyl CW39 ρ-hydroxy ρ-anisole CW69 2,4-diol cyclohexyl 
CW5 tetralin isopentane CW40 ρ-hydroxy (+/-)phenyl 
ethyl 
CW72 2,3-diol isopropyl 
CW6 tetralin sec-butyl CW41 tetralin n-octane CW76 σ-hydroxy cyclohexyl 
CW7 tetralin isopropyl CW42 tetralin benzyl CW77 σ-hydroxy cyclopentyl 
CW8 tetralin neopentane CW43 tetralin n-undecane CW81 σ-hydroxy σ-phenol 
CW9 tetralin isobutyl CW46 tetralin cyclopentyl CW82 2,3-diol σ-phenol 
CW13 tetralin phenylethane CW47 tetralin n-cyclohexyl CW84 ρ-hydroxy (+/-)-2-
propanol 
CW15 tetralin σ-xylene CW48 napthyl n-dodecane CW85 ρ-hydroxy (R)-2-
propanol 
CW16 tetralin anisole CW49 napthyl n-octane CW86 ρ-hydroxy (S)-2-
propanol 



































CW28 ρ-hydroxy isopropyl CW57 napthyl ρ-phenol CW98 σ-hydroxy (S)-2-
propanol 
CW29 m-hydroxy n-propyl CW59 napthyl benzyl    
CW30 σ-hydroxy n-propyl CW60 napthyl σ-phenol    
CW31 m-hydroxy isopropyl CW61 σ-hydroxy ρ-phenol    
CW32 σ-hydroxy isopropyl CW62 2,4-diol isopropyl    
CW33 H n-propyl       























CW1 30.4 CW27 10.3 CW49 28.4 CW81 30.2 
CW2 69.1 CW28 37.3 CW50 29.9 CW82 67.5 
CW3 25.2 CW29 98.4 CW51 17.9 CW84 30.2 
CW4 17.1 CW30 53.7 CW52 17.8 CW85 7.2 
CW5 47.6 CW31 34.4 CW54 62.1 CW86 17 
CW6 37.4 CW32 63.9 CW55 52.6 CW90 37.4 
CW7 98.6 CW33 60.4 CW56 54.9 CW91 20.5 
CW8 86.6 CW34 34.2 CW57 54.4 CW92 26.1 
CW9 95.4 CW35 24.5 CW59 32.9 CW93 28.7 
CW13 60 CW36 29.5 CW60 53.2 CW95 18.8 
CW15 26.3 CW38 57.9 CW61 55.1 CW96 66.8 
CW16 47.6 CW39 33.8 CW62 43.4 CW97 5.1 
CW18 17.6 CW40 98.7 CW63 45.6 CW98 52.5 
CW20 36.3 CW41 77.6 CW64 48.1   
CW22 24.6 CW42 55.3 CW68 33.1   
CW23 19.4 CW43 49.4 CW69 60.6   
CW24 45.6 CW46 25.3 CW72 39.9   
CW25 29.4 CW47 58.6 CW76 26.6   
CW26 35.2 CW48 42.6 CW77 32.8   
 
4.4 Arylmethyleneimidazolone Chromophore Properties 
 
The photo physics of GFP, specifically its intense fluorescence, has made it a cornerstone of 
biological imaging. A major contributor to the strong fluorescence observed from GFP 
chromophore is the β barrel its enclosed in. In addition to stability and protection from quenching 
via the external surroundings, residues in the local protein environment assist in excited state 
proton transfer generating the anionic species of the chromophore ultimately responsible for its 
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emission. The β-barrel enclosure restricts rotation of the chromophore preventing cis/trans 
isomerization from occurring which is present in solution with unbound chromophores. In the 
absence of the protein host synthetic chromophores have drastically different photo physic 
properties displaying fluorescence several magnitudes less than wild type GFP [38]. Even upon 
denaturing of wild type GFP fluorescence is weak at best. Reformation of GFP leads to 
regeneration of the chromophore and restoration of fluorescence [32]. Baldridge et al has 
demonstrated that enhancement in fluorescence of the synthetic chromophore can be achieved 
via encapsulation [39]. In addition to enhancement Baldridge could demonstrate proof of this 
concept with select AMI chromophores and human serum albumin (HSA) [40].  This motivation 
heightened our belief that AMI chromophores could not only serve as estrogen receptor 
modulators but also exhibit “turn on” fluorescence. Envisioning the nuclear receptor as the host 
protein and the LBP as the restricting cavity like that of the β-barrel upon binding the 
synthetically generated AMI can undergo similar excitation process as wild type GFP thus 
creating a fluorescently trackable modulator in one package where enhanced fluorescence 
implies binding.          
The spectroscopic properties of the AMI compounds synthesized in this work have been 
explored and are listed in the Appendix A. All synthesized compounds absorbed in the visible 
range, with λmax (abs) 345nm-402nm and have fluorescence emissions ranging from 414nm-
600nm. Shorter absorption wavelengths were observed with compounds lacking electron donors 
at the ρ-position of the aryl ring, specifically those possessing the tetralin core.  
4.5 Biological Assay Screens  
In addition to ligands specifically designed using the above rationale to serve as agonist for ERα, 
compounds that had been previously generated for our AMI library that fit the profile were 
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evaluated as well. The increase in presence of and accessibility to small molecule chemical 
libraries for attenuation of physiological process garners the demand for feasible, reliable and 
time considerate approach to screening. Herein we utilize two screening approaches first 
chemical complementation as an initial screen and chemiluminescence as a second screen.  
4.5.1 Chemical Complementation 
 
Broadly defined chemical complementation is genetic selection highlighted using a small 
molecule. Though used to describe a variety of experimental systems, the underlying theme of 
chemical complementation is the marriage of a molecular chemical entity and a “system” 
wherein genetic selection can be applied to evaluate molecule-system association. Herein we use 
a three component (yeast three hybrid) system linking the survival of yeast to the ability of a 
small molecule modulator to activate nuclear receptor transcription. Single and dual component 
yeast hybrid systems for ligand-receptor survival have been extensively investigated however the 
three-hybrid system most suits our purpose [2]. Employing yeast as a host is ideal as yeast is an 
organism void of endogenous nuclear receptors thereby eliminating the concern of alternative 
competing receptor-ligand interaction. The yeast strain used (Saccharomyces cerevisiae – PJ69-
4A) contains Gal 4 response elements (Gal4RE) used to control the expression of genetic 
selection genes involved in the histidine (HIS3) and adenine (ADE2) biosynthetic pathway. 
Transformed in the yeast are two fusion proteins, a Gal 4 DNA binding domain (Gal4DBD) 
fused to a nuclear receptor ligand binding domain (LBD) and a Gal 4 activation domain (GAD) 
fused to a nuclear receptor co-activator (SRC-1). At the core of chemical complementation 
binding of a ligand to the nuclear receptor LBD promotes binding of the LBD: Gal4DBD fusion 
with the Gal4RE thus prompting a conformation change of the receptor allowing for recruitment 
of the GAD:SRC-1 fusion. Completion of this cascade actuates transcription of selective genes 
57 
 





Chemiluminescence is a process by which a chemical reaction generates sufficient energy to 
produce an excited stated resulting in photon emission where upon relaxation to its 
corresponding ground state emits light. When the photon emitting reaction is enzymatically 
driven, the process is specifically designated bioluminescence with the enzyme termed luciferase 
and the photon emitting substrate termed the luciferin. Largely used as a genetic reporter 
expression of luciferase can be affixed to a cellular event linking bioluminescence to a 
quantitatively observable process detectable by a signal. Cellular based assay’s formatted to 
exploit bioluminescence are widely accepted as a viable methodology of high throughput 
screening compound evaluation. Herein we utilize a luciferase reporter gene assay to measure the 
efficacy of our ligands with estrogen receptors α and β as well as additional nuclear receptors. 
4.5.3 Nuclear Receptors and Reporter Gene Assay 
 
Luciferase reporter assays have been employed with success for receptors such as G-protein 
coupled receptor and nuclear receptors. In the case of nuclear receptors cloning of the receptors 
regulatory region of interest takes place upstream of the luciferase reporter while downstream of 
the reporter houses a promoter with a hormone response element or Gal4 binding domain and a 
mammalian promoter. In turn ligand binding of the nuclear receptor in the proximity of the 
promoter activates luciferase gene expression. Firefly and Renilla luciferase are commonly used 
for this form of assay with the latter being used as a co-reporter. Firefly luciferase functions 
combining beetle luciferin with ATP, to form luciferyl-AMP as an enzyme bound intermediate. 
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This intermediate reacts with O2 to create another bound intermediate, oxyluciferin, in a high-
energy state. For our assay purpose wild-type estrogen receptor α ligand binding domain was 
fused to Gal4DBD, this plasmid was then cloned into mammalian expression vector pCMX. This 
plasmid fusion operated under the control of a cytomegalovirus (CMV) promoter.  The reporter 
plasmid, p17*4TATAluc, contained the Renilla luciferase gene under the control of four Gal4 
response elements located upstream from a minimal thymidine kinase promoter served as co-
plasmid for dual reporting. The pCMXβgal, a plasmid containing the β-galactosidase gene under 






















Figure 4.9 Screening analysis method for evaluating GFP inspired agonist with nuclear receptors. 
A) Chemical complementation via the application of the yeast three hybrid system. Yeast 
survival is a direct result of the ligands ability to bind and activate the nuclear receptor 
transcription machinery. B) Luciferase assay production of the enzyme luciferase is controlled 
by the ligands ability to bind to the nuclear receptor. Luciferin in the presence of luciferase 
generates light C) Reaction that characterizes the production of light in the luciferase assay. 















4.6 Generation I Results 
 
4.6.1 Chemical Complementation 
 
AMI ligands based on rational drug design as described above were evaluated for activation of 
estrogen receptor α using chemical complementation as an initial screen. With the employment 
of the Gal 4 protein, a ligand independent transcription factor, two fusion proteins were 
constructed: Estrogen Receptor α ligand binding domain (ERαLBD) was fused to the Gal 4 DNA 
binding domain (DBD) generating the ErαLBD:Gal4DBD protein fusion. Estradiol (E2) the 
endogenous ligand for the estrogen receptor was tested and exhibited growth resulting in an 
optical density (OD) of 0.5 ± 0.04. To ensure observed responses was restricted to the ligand, the 
vehicle (ethanol:dmso) designated no ligand or NL was tested in which no growth was shown 
yielding an OD of 0.04 ± 0.02. The Gal4 protein (intact) was used as a positive control providing 
an OD of 0.6 ± 0.1. Of ligands designed to investigate hydrogen bonding ability only activated 
growth was observed for CW32 producing an optical density (OD) of 0.8 ± .1.  
Screening ligands centralized on exploration of ligand volume did not result in observed 
activation, however interesting comparison can be made from CW32 and CW30. Observed 
activation can be noted in CW32 where the only contrast is conversion of the isopropyl to a 
propyl group supporting the implication positive influence from isopropyl groups.  
Compounds designated to evaluate molecular topography also produced no new led indicating 
that lowering the overall polarity of the compound for this type of ligand may not directly result 
in enhanced activity. Sensitivity for both AMI's and estradiol were measured via dose response 
curve with ligand concentration ranging from 10-5 to 10-12 M. Estradiol is several orders of 
61 
 
magnitude more sensitive than CW32. Much of the subset did not induce growth however the 
discovery of activity with CW32 prompted further screening. 
Table 4.4 Chemical Complementation Results of 1st Generation Ligands. Results of 1st 
generation compounds indicating growth in ligand CW32 and control estradiol (E2). No growth 
was observed in the vehicle consistent growth was observed in the positive control Gal 4. 
Ligand Optical Density Fold 
Induction 
Gal 4 
Vehicle 0.04 ± .001 1 0.6 
E2 0.5 ± 0.03 11 0.6 
CW32 0.8 ± 0.1 21 0.6 
 
 
Figure 4.10 Generation I dose response curve in yeast. Active compound CW32 (blue) and 
controls estradiol (E2 black) and ethynyl estradiol (EE-2 orange) were included. CW32 is 



































































































4.6.2 Luciferase Results 
 
To determine whether observed activation in yeast existed within mammalian cell, human 
embryonic kidney 293T (HEK293T) cells were transfected with the plasmid 
pCMXwithERαLBD. Like the fusion protein used in chemical complementation this plasmid 
contains the Gal4DBD (GBD) fused to the wild-type ERα ligand binding domain LBD. The 
pCMXβgal, a plasmid containing the β-galactosidase gene under the control of the mammalian 
CMV promoter, was also used as an internal standard.  Ligands were added, and cells were 
harvested 48hrs after the addition of ligand and analyzed for luciferase and β-galactosidase 
activity.  All data points represent the average of triplicate experiments normalized against β-
galactosidase activity, standard deviations are represented using error bars. 
Utilizing the bioluminescence assay the initial subset of AMI ligands screened in yeast were 
assayed in human embryonic kidney 293T cells (HEK293T) for comparison purpose. Ligand 
responses are reported as fold inductions (quotient of ligand response over vehicle). Estradiol 
(E2) was added as a control and to ensure observed responses were restricted to the ligand, the 
vehicle (ethanol:dmso) was tested (NL = no ligand) and normalized to 1. E2 exhibited fold 
induction of 26 ± 0.7. Ligands exemplifying responses 90% or greater than that of the E2 were 
















































































4.6.2.1 Hydrogen Bonding Network 
 
Recall the hydrogen bonding network can be viewed as a function of three principal amino acids 
Gln-353 and Arg-394 at the rear of the ligand binding pocket and His-524 at the front of the 
pocket. Ligands that were generated to explore preservation of a hydrogen bonding network 
revealed activation from several compounds with a range of potency from modest to high. 
Ligands CW24 – CW33 were designed to explore interactions with Gln-353 and Arg-394. 
Compounds CW25 and CW27 both of which possess phenols however due to steric crowding the 
hydrogen is inaccessible for donation resulted in fold activation of 1.49 ± 0.1 and 2.4 ± 0.6 
respectively. CW33 which completely removes the core (A-Ring) phenol abolishes all activity 
producing a fold induction of 1.5 ± 0.1. This data supported our belief that the core hydroxyl 
plays a physical donor-acceptor role and is not reduced to solely electronic contribution. 
Compounds CW28, CW29, CW30, CW31, CW32 all of which possess phenols as accessible 
hydrogen bond donors, all displayed activation except CW31 which produced a fold induction of 
2.6 ± 0.1.  CW28 display the lowest fold induction of the group at 11 ± 1.4. Both ligands CW29 
and CW30 are comparable in fold induction 18 ± 1.1 and 15 ± 0.7 respectively. Ligand CW32 
produced the highest induction of the group at 60 ± 6.2 more than double the response of E2. 
Although ligands CW28 and CW32 only differ in substitution pattern of the phenol there is a 
pronounced distinction in activation levels with CW32 displaying induction value 6-fold higher. 
CW24 possess a methylated hydroxyl rendering the ability of the core phenol to solely hydrogen 
bond acceptor yields a fold induction of 3.1 ± 0.3. While this fold activation is slightly higher 
than that of non-activating ligands it does not compare to that of ligands with donor capabilities. 
Screening of compounds designated to explore the role of the core (A-ring) phenol with Gln-353 
and/or Arg-394 illustrated the necessity for a hydrogen bond donor. 
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Table 4.5 Exploration of the role of the A-ring hydroxyl. Ligands designed to explore the role of 
the A-ring hydroxyl as a hydrogen bond donor or receptor reveals an activation is observed when 










Ligands CW34, CW36, CW39, were screened to assess if interaction with His-524 are necessary 
and if so are donor or acceptor capabilities optimal. All three ligands have a phenol on the A-ring 
in the para position and an aryl phenol on the nitrogen. CW34 and CW36 are both hydrogen 
bond donors varying only in the substitution pattern of the N-arylated phenol with the first being 
para and the latter ortho. CW34 produced a fold induction of 22 ± 0.1 while moving the phenol 
to the ortho position (CW36) annulled all activity with a fold induction of 1.1 ± 0.1. Lastly 
CW39 is identical to that of CW34 except the noncore phenol is capped restricting ability to only 
hydrogen bond acceptance. Removing hydrogen bond acceptor capabilities significantly 
diminished fold induction to 13 ± 1.3.  It appears better activity is achieved with a hydrogen 





CW24 3.1 ± 0.3 Acceptor 
CW25 1.4 ± 0.1 Donor (Sterically 
Hindered) 
CW27 2.4 ± 0.6 Donor (Sterically 
Hindered) 
CW28 11 ± 1.4 Donor 
CW29 18 ± 1.1 Donor 
CW30 15 ± 0.7 Donor 
CW31 2.6 ± 0.1 Donor 
CW32 60 ± 6.2 Donor 
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Table 4.6 Hydrogen Donor vs Acceptor Role of Ligand with His-524. Fold induction as a 
function of substituents designed to assess the ligands role as a hydrogen donor or acceptor as it 
relates to histidine-524. Activation is achieved with both the ligand as a donor or acceptor 
however enhanced activation is seen with the donor. 
Ligand Fold 
Induction 
Role with His-524   
Donor/ Acceptor 
CW34 22 ± 0.1 Donor 
CW36 1.1 ± 0.1 Donor 
CW39 12 ± 1.3 Acceptor 
 
4.6.2.2 Molecular Topography  
 
Attenuation in molecular topography was achieved by incorporation of tetralin cores CW01, 
CW07, CW16, CW18, CW46, CW47 or napthyl cores CW51, CW57, CW59, CW60. As 
reported in Table no activation was observed in ligands bearing tetralin or napthyl additions. It is 
important to note that modification in the scaffold can also contribute to variations within ligand 














Table 4.7 Perturbation of Ligand Core. Variation effect on polar surface area Against Activation 
for different ligand cores. ACD cores promote the best activation of the scope of cores we 






Log P Fold 
Induction 
I. Tetralin    
CW 7 35 4.6 1 
CW 18 55 4.7 1 
II. 
Napthyl 
   
CW51 35 3.3 2.4 
CW57 55 3.2 2.1 
III. 
ACD/AMI 
   
CW32 55 1.9 60 
CW34 75 1.6 22 
IV. ABCD    









4.6.2.3 Ligand Volume 
 
Ligand volume and size prove to be an interesting dynamic mainly because variation to explore 
hydrogen bonding network or molecular topography often yields alteration in ligand volume-
shape. Several factors have been observed within ligand volume perturbations, table illustrates 
the volume and consequently effect on fold induction for active ligands thus far.  
Table 4.8 AMI Molecular Volume & Fold Induction. The above table demonstrates the 
relationship between molecular volume and fold induction displaying as molecular volume 






Estradiol (E2) 268 
(245)* 
26 ± 0.7 
CW32 230 60 ± 6.2 
CW34 259 22 ± 0.1 
CW39 277 12 ± 1.3 
CW63 268 13 ± 1.7 
 
CW38 270 8.6 ± 1.2 
CW35 253 6.8 ± 0.4 




In general, it’s clear that the closer in volume to estradiol an increase in potency can be observed, 
however after estradiol’s volume a significant drop-off in activation occurs. In ligand families 
were volume is conserved as is the case of isomers for instance CW32 and CW30 which differ in 
N-alkylation isopropyl vs propyl respectively yields distinct differences in activation. The same 
is observed with isomeric family CW32, CW31, CW28, were volume remains unchanged 
however reposition of the hydroxyl moiety on the aromatic ring can demonstrate superior, 
abolished or diminished fold induction as demonstrated in table. Ligands CW35 and CW38 
explored if the potency enhancement observed from spacing of the isopropyl substituent could be 
the start of a larger ring system. Ligands CW35 and CW38 exhibited modest activity with fold 
induction values of 6.8 ± 0.4 and 8.6 ± 1.2 respectively the lowest response of the subset. 
Indicating that the isopropyl spacing has a limitation and is not further enhanced by generating a 
larger cyclic system. 
Table 4.9 Isomeric AMI Molecular & Fold Induction. The above table illustrates the effect of 
rotating the phenol in the A-ring on isomers of CW32 removing interaction with the receptor 






CW32 230 60.2 ± 6.2 Leu-346 
CW28 230 10.5± 1.42 Arg-394, 
Glu-353 






4.7 Structure Activity Relationship Compounds 
 
Ancillary AMI ligands were synthesized by exploiting key activation criteria provided from 1st 
generation results. Activating compounds were examined against compounds of similar nature 
that did not activate to devise a structure activity relationships diagram. The AMI ligand can be 
divided into three portions for examining and iteration development: A-ring, core, and D-ring.  
4.7.1. A-Ring 
 
The hydroxy on the A-Ring proved to be not only a necessity for activation but also selective in 
its position and relationship. Comparison of compounds CW33 against CW29, CW30, or AB18 
were the only structural distinction is the presence of a hydroxyl group illustrates the need for the 
moiety to induce activation. The relationship for the hydroxyl as a hydrogen bond donor is 
clearly defined by the lack of activation in compounds that possesses the hydroxyl but limit its 
role to hydrogen bond acceptor (CW24). Lastly within isomeric families such as CW28, CW31, 
CW32 and AB18, CW30, CW29 shift in activation can be viewed as a direct consequence of 
preference in hydroxyl position.     
4.7.2. Core-Scaffold  
 
Modifications in the core structure demonstrated the complexity with this class of ligand for 
generating compounds adhering to volume restrictions while minimizing polarity. Comparison of 
unsubstituted tetralin, naphthyl, aryl methylene and indole (previously generated) cores revealed 
aryl methylene imidazolone core to have the lowest molecular volume. This is beneficial because 
it allows for more substitutions to be made while still heeding to pocket volume restrictions this 
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aided in our decision to focus predominately on the aryl methylene imidazolone core. While 
focus was given to aryl methylene core compounds without inclusion of other parameters such as 
hydrogen bond contribution of the A-ring the possibility that additional types of cores including 
indoles and naphthyl cannot be discarded if properly attenuated.   
4.7.3. D-Ring 
 
Activation appears to be tolerant to several D-Ring substituents with preference for small 
nonpolar groups such as propyl and isopropyl, small cyclic rings and hydroxylated aromatic 
rings. Comparing D-Ring substituents of compounds all bearing a 4-hydroxyl substitution on the 
A-Ring provides the effect from the substituent. Compounds CW28, AB18, CW35, CW34, 
CW38, CW39.  CW34 show aromatic hydroxyl rings contribute with the largest activation of the 
set however with a significant contribution coming from aromaticity and hydroxyl as compared 
with CW38. The second highest activation of the above set was generated by CW39 
demonstrating that while preference may be for a hydrogen bond donor incorporation of a 
hydrogen bond acceptor still produces activation higher than that of compounds lacking either 
capability. Additional substituents isopropyl (CW28), propyl (AB18), cyclopentane (CW35) all 
having comparable activation.     
Consideration was still giving to our 3 established criteria of hydrogen bonding, topology and 
ligand volume while constructing derivatives.       
4.7.4 Hydrogen Bonding Network 
 
To maximize hydrogen bonding network, additional hydroxyl moieties were incorporated in the 
A-ring phenol generating a series of diols. Increasing the number of hydroxyl group on the core 
phenol should ideally increase the number of hydrogen donor-acceptor contacts between critical 
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amino acids and the ligand thus strengthen the hydrogen bonding network ultimately resulting in 
enhanced binding and activation.  
4.7.5 Ligand Volume and Size 
 
Effort to increase activation while maintaining general ligand volume and size was conducted by 
combining active D-Ring substituents with active A-ring cores. Using cores substitution that 1st 
generation compounds have shown to be preferred along with front end substituents that have 
shown to be favorable should result in optimal compounds. As illustrated in the figure below 
with the core of CW32 and the substituents of CW34 to generate CW61.  
4.7.6 Molecular Topology 
 
Due to the incorporation of additional hydroxyl moieties and hydroxylated aromatic rings on 
existing polar cores the molecular topology (polar surface area) will increase. The premise is that 
the modifications being made are more favorable and create interactions that neglect the effect 




Figure 4.13 Strutrue activity relationship compounds. A 2nd generation of compounds were 
synthesized after data anaylsis of exploration compounds.   
 
4.8 Generation II Results 
 
In accordance with the biological screening assay protocol explained in section 4.5 of this 
chapter 2nd generation compounds were tested initially via chemical complementation and 
secondly via luciferase assay. 
4.8.1 Chemical Complementation 
 
AMI ligands based on 1st generation structure activity relationship studies were evaluated for 
activation of estrogen receptor α using chemical complementation as an initial screen. As 
detailed previously estradiol (E2) the endogenous ligand was used as a positive control and 
exhibited an optical density (OD) of 0.5 ± 0.1. Precaution was taken to ensure that observed 
responses was restricted to the ligand, the vehicle (ethanol:dmso) designated no ligand or NL 
was tested in which no growth was observed yielding an OD of 0.04 ± 0.04. The Gal4 protein 
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(intact) was used as an additional positive control given an OD of 0.7 ± 0.1. Chemical 
complementation screening of 2nd generation resulted in no observation of activation from any of 
the next generation compounds.   
 
Figure 4.14 2nd Generation chemical complementation results. Evaluation of ligands designed 
from generation I results.  
4.8.2 Luciferase Assay 
 
Utilizing chemiluminescence as a screening tool previously outline in this chapter 2nd generation 
compounds were screened via luciferase assay. It is important to note that just because activation 
was not observed within the chemical complementation yeast assay that does not guarantee no 
activation will be observed in this assay as well.  
4.8.2.1.  Hydrogen Bonding Network 
Multi-substituted 3,4-diol (CW52) and 2,3-diol (CW72) were synthesized with n-propyl and 
isopropyl alkylations respectively 2,4-diol (CW63) an analog of CW34 was also synthesized. 
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Interestingly the construction of the diols resulted in active compounds for CW63 and CW72 but 
lead to significant loss in activity from their parent compounds with fold induction values of 13 ± 
1.7 and 5.4 ± 0.4 whereas the combination of hydroxyl to the para and meta position generating 
CW52 abolished all activity. This leads us to believe that the incorporation of more diols does 
not ensure strengthening of the hydrogen bonding network and in turn more potent compounds.  
4.8.2.2.    Ligand Volume -Size 
 
In an initiative to further understand the role of volume with activating compounds specifically 
the effect of small nonpolar substituents such as the isopropyl in CW32 a series of analogues 
were synthesized. These analogues all shared the ortho phenolic ring as in CW32 however varied 
in amide substitutions but only containing substituents of active compounds. This series 
generated CW61, CW76, and CW77 containing p-aminophenol, cyclohexyl and cyclopentyl 
substituents respectively. While activity remained in CW61 the shift in the core phenol caused 
fold induction of 13 ± 3.3, dramatic decrease in activation from CW34 and CW32. All activity 
was abolished with ligands CW76 and CW77 confirming a preference for small non-polar 
substituents.   
4.8.2.3.    Molecular Topology 
 
 Lastly to gather insight regarding molecular polarity as it pertains to the top two activators 
CW32 and CW34. The tetralin analogues CW7 and CW18 were synthesized as well as napthyl 
analogue CW57 were synthesized. Based upon previous results it was not surprising that the 
napthyl nor tetralin cores produced no response.  
Dose responses were conducted on top active compounds to determine the degree of sensitivity 




Figure 4.15 2nd generation ligands screened in luciferase assay. Ligands designed from the 
development of SAR of 1st generation were tested for activity.  
 
Figure 4.16 Dose Response for top ERα agonist. Generation I and II screening in luciferase assay 
revealed CW32 (blue) and CW34 (yellow) as top activators. While high in potency estradiol 
remains more sensitive.   
 
To correlate the activity in vivo with in vitro and binding analysis, the top two activators (CW32, 
CW34), a modest activator (CW72) and a non-activator (CW33) were subject to testing using 
TR-FRET (time resolved fluorescence resonance energy transfer) competitive binding assay. 
This assay employs estrogen receptor α labeled via a GST tag bound to its anti-GST antibody 
that is terbium labeled. Competitive binding to estrogen receptor α occurs via our AMI agonist 





















The proximity of labeled ligand and the tagged antibody directly corresponds to the strength of 
the FRET signal. Here successful displacement of the tracer by our AMI agonist will result in a 
decrease in FRET signal. Results of a 10-point titration produced dose response curves that are 
within agreement with our observations. The highest activator CW32 caused the largest 
displacement at the highest concentration, followed by CW34 and only modest displacement 
observed with CW72. Lastly CW33 demonstrated no displacement which was expected based 





Figure 4.17 Structure of GFP chromophore inspired active ligands and fold induction. Active 





Figure 4.18 TRFRET results of top activators and lowest activator. TRFRET results of top 
activator and lowest activator confirmed luciferase assay results of binding with ligands 
successfully displacing estradiol. CW33 was used as a negative control (non-binder) which showed 
no displacement. 
 
4.9 Ligand Activation Rationale 
 
 As previously shown in literature ligands that stimulate a response from the estrogen receptor 
either as agonist or antagonist arise from a diverse background of compounds however all share 
commonalities highlighted as essential for activation. In our exploration of GFP chromophore 
inspired compounds as a viable class of estrogen receptor agonist main guidelines supported in 
literature were observed to identify the role played with this class of molecule. In designing this 
class of ligand attention was giving to the following 3 criteria: 1) preservation of hydrogen 
bonding network via key amino acid residues within the ligand binding pocket 2) size and 
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volume occupied by the ligand and lastly 3) molecular landscape of the ligand with respect to 
polarity.    
4.9.1 Hydrogen Bonding Network 
 
The modulation of the hydrogen bonding network between AMI ligands and the estrogen 
receptor α ligand binding pocket demonstrates a pronounced effect on activation. While possible 
weak polar interactions with the aromatic ring contribute to activation, the ability of the phenol 
to participate in hydrogen bond donation seems to be priority for activation. Docking of several 
active AMI ligands indicate ligand-residue contacts that preserve the role of the phenol moiety 
with known residues Arg-394 and Gln-353. The phenol in ligand CW28 exhibits hydrogen bond 
donation reminiscent to estradiol's A-ring, where it is located 2.6A3 and 3.7A3 from Arg-394 and 
Gln-353 respectively. The lack of this hydrogen bond network resulted in a lack of activity in 
compounds CW25 and CW27 where the phenol is inaccessible due to steric hindrance and 
CW33 where the phenol is non-existent. This led to the rational that preserving the hydrogen 
bond network and ensuring that the hydrogen bond network is sterically favorable, results in 
activation.  Ligand CW24 bears a methylated phenol revoking hydrogen bond donation ability 
and consequently abolishing activity thus supporting the role and need of a hydrogen bond donor 
on the A-ring.  While some of the active ligands do not maintain the Arg-394 or Gln-353 
contacts the H-bonding donation network remains consistent. Case in point are modulators 
CW32 and CW30 were the phenol hydrogen participates in H-bonding with the backbone 
carbonyl of Leu-346 solely in CW32 and cooperatively with Gln-353 in CW30. It can be 
concluded that to achieve activation with this class of ligand a hydrogen bonding network 
between the ligand and ligand bonding pocket must be established. Our data supports that this 
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network can be inclusive of amino acids residues or their backbones. Not only is this relationship 
a requirement but our evidence supports it is the most important contributing factor.     













Figure 4.19 Modeling of the hydrogen bonding network between AMI ligands and the 
ERα:LBD. A) Phenolic A-Ring in CW28 participates in H-bonding with ARG-394 and GLU-
353 residues. B) Phenolic A-Ring in CW32 participates in H-bonding with LEU-346 backbone 
carbonyl.  C) Phenolic A-Ring in CW30 participates in joint H-bonding with GLU-353 and 
carbonyl of LEU-346. D) In ability of phenolic A-ring within CW24 to participate in H-bonding. 
The hydrogen bonding network is extended to the front of the AMI ligand involving His-524. 
Linked to the 17β position of estradiol, His-524 ability to serve as a hydrogen bond donor has 
been highlighted as a key residue within the LBP [37]. The imidazolone carbonyl in our ligands 
possess the same ability as the 17β secondary alcohol in estradiol to participate in hydrogen bond 
accepting. Comparative distance of the carbonyl to His-524 residue yields results farther than 
that of estradiol relationship however it is possible that this process is water mediated. The 
carbonyl distance of CW28, CW30 and CW32 are 4.8A3, 5.5A3 and 5.1A3 respectively. It is 
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worth noting that the carbonyl (AMI) and alcohol (E2) are not in perfect alignment, likewise the 
carbonyl is rotationally restricted as compared to a secondary alcohol. The role of the oxidation 
of a secondary alcohol to a carbonyl is most notably demonstrated in the conversion of estradiol 
to estrone although this conversion resulted in diminished activity from that of estradiol [38]. It 
can be postulated in the case of these ligands that the carbonyl has a positive contribution with 
the resonance structure of the amide leading to a more enhanced hydrogen bond acceptor thus 
keeping the hydrogen bond network intact.  
In addition to external hydrogen bonding between the ligand and the LBP a second type of 
hydrogen bonding may exist solely involving the ligand. Intramolecular hydrogen bonding can 
be present amongst certain ligands in this class case in point CW32. The nitrogen incorporated in 
the imidazolone ring and the phenol in ortho-substituted AMI ligands are positioned to 
participate in intramolecular hydrogen bonding. This potential preservation of hydrogen bonding 
network is more evocative of estradiol's B-ring and may provide prospective into discrepancies 
in isomeric activation. Reduction in activation occurs within CW32 series as the phenolic 
hydroxyl group shifts from ortho to para consequently as the intramolecular bonding distance 
between the hydroxyl group and the nitrogen increases. Analogue CW31 where the hydroxyl 
group is in the meta position and devoid of the ability to hydrogen bond with itself or the LBP all 
activity is annulled. The resurgence of activity with CW28 is a testament to the prominence of 
the need for hydrogen bonding network (external) however the contrast in activation between 




Figure 4.20 Exploration into the role of His-524 with AMI ligands comparative to that of E2.   
A) Carbonyl of CW28 interacting possibly via water mediated process with His-524 residue.    
B) Carbonyl of CW30 interacting possibly via water mediated process with His-524 residue.    
C) Carbonyl of CW32 interacting possibly via water mediated process with His-524 residue.    
D) Hydroxyl of E2 preserving H-bonding network with His-524 residue. 
  
4.9.2 Ligand Volume(Shape/Size) 
 
Molecular volume and estrogen receptor α activation for this class of ligand display an inverse 
relationship. Our data suggest that as molecular volume increases activity diminishes. Using 
molinspiration cheminfomatics software [34] molecular volumes of select active and non-active 
AMI ligands were calculated. Favorable molecular volume for this class of ligand is roughly half 





molecular volume of estradiol ligand at 245A3. In our data set top activator CW32 is comparable 
with a predicted value of 230A3. The role of molecular volume can be viewed in two 
perspectives within a series of isomeric compounds and across a family of compounds. Within 
an isomeric family such as CW28, CW29, CW30, CW32 where volumes are identical at 230A3 
hydrogen bonding network preservation becomes the determining factor of activation.  
However, when looking across families of compounds for instance CW32, CW34, CW39 
molecular volume play a significant role following an inverse relationship. Anomalies within this 
trend are observed across families wherein a ligand larger in volume maybe more active than a 
smaller one as shown in the case of CW35 and CW63, which includes. Rationale for this can be 
provided by discrepancies in hydrogen bonding ability. Interestingly compounds that have ideal 
molecular volume CW33 at 222A3 but lack hydrogen bonding displays no activity. It can be 
concluded for this class of ligand that while hydrogen bonding ability is essential for activation 
to occur, molecular volume can be viewed as an enhancing factor that possess threshold 







Figure 4.21 Modeling of volume and 
size of AMI ligands in comparison with 
that of E2. A) Illustrates the volume of 
the pocket (mesh) occupied by E2. B) 
Illustrates the volume of pocket 
occupied by CW32. C) Illustrates ligand 





4.9.3 Molecular Topology-ACD ring effectiveness 
 
Topology also plays a substantial role in binding with the LBP being largely hydrophobic and 
size restricted. ERα crystallography complexes with ligands, and site mutagenesis studies 
indicate a hydrophobic LBP intolerant to polar substitutions [35]. Using Katzenellenbogen 
pharmacophore as our guideline certain substituents had to be included locking in a specific base 
level of polar surface area. The stipulation of a phenolic A ring is consistent with what we 
observed for all active AMI ligands. The incorporation of hetero-cyclic rings to provoke estrogen 
receptor modulation is not unprecedented and has been employed in studies to show modest 
relative binding affinities [36]. It is plausible that the modest affinity is a direct result of the 
introduction of a higher polar topography.  As expected the inclusion of the imidazolone in our C 
ring scaffold adds polarity elevating our ligands polar surface area to that above estradiol, but 
whether the deviations are considerable or minuscule are dependent upon the amide alkylation’s 
and aryl substitutions. The D ring as expressed by Katzenellenbogen pharmacophore as generally 
aromatic is consistent with several of our active compounds with higher levels of fold activation 
observed for aromatic rings CW34, CW39, CW63 and CW61 then for non-aromatic rings CW35 
and CW38. Consequently, the addition of the aromatic ring increases the polar surface area. 




polar surface area is lowered although still above that of estradiol. The subset did contain 
analogues that were lower in polar surface area than estradiol for example CW7 at 35A however 
deviations from pharmacophore features and a high molecular volume prevent activation. 
Currently we can conclude that for this class of ligand the small polar aromatic cores are best 
when in conjunction with small non-polar substituents, however at present an optimal molecular 
topology has not been determined.  
In addition to polar surface area the effectiveness of the ACD ring system plays an integral role. 
The figure below illustrates that within the pocket the ACD ring system shares alignment 
commonalities with that of the indigenous ligand estradiol. The hydroxyl moiety of the GFP 
inspired agonist such as CW32 aligns with that of the methyl of estradiol and faces in the same 
plane as the hydroxyl in estradiol. Good alignment occurs within the A-ring of both ligands even 
though the hydroxyl moieties do not align. This strengthen the rationale behind the usage of the 
ACD ring system and its interactions within the estrogen receptor.  
 






                         
 
CW32 Carbonyl E2 hydroxyl CW32-A Ring 
E2- A Ring 
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Additional support for the GFP inspired chromophore as estrogen receptor agonist claim can be 
found by examining the distance between specific atoms. The interatomic distance of the 
oxygens A-ring phenol and secondary phenol in estradiol has been shown to be at an optimal 
spacing to promote residue interaction within the ligand binding pocket. The 
arylmethyleneimidazolone core agonist adopts similar atom spacing with the A-ring and the D-
ring substituents. As highlighted in table 4.10 certain D-ring substitutions can achieve this 
interatomic distance allowing the ACD ring system to access the same interactions as that of the 
indigenous ligand. As highlighted in the table below and illustrated in figure 4.22 CW34 is one 
such ligand that the interatomic distance from the phenol (A-ring) to that of the phenol (D-ring) 
is like that of estradiol. Similar observations can be made for ligands other ligands including top 
activator CW32. However, in the absence of a second phenol the carbonyl group on the 
arylmethyleneimidazolone core can be used as a second marker.  
Table 4.10 Interatomic distance and fold induction. Inter atom distance for the GFP-inspired 
chromophore ligand oxygen to oxygen distance is like that of estradiol. Distance is conserved in 
non-binders however other factors such as hydrogen bonding play a critical role in activation. * 
denotes experimental value  
Ligand Fold Induction Molecule Distance 
Length (A) 
Estradiol 26 ±0.7 10.8 (10.9) * 
CW32 60 ± 6.2 7.6 
CW34 22 ± 0.1 13.5 
CW33 Not active 7.2 
 
 




Figure 4.23 Oxygen to oxygen distance for estradiol and top two activators. The interatomic 
distance is illustrated in red with ligands bearing similar distance but different ring systems. 
 
4.10 SUMMARY 
The development of ligands for estrogen receptor α continue to be of high importance as both 
agonist and antagonist. Herein we have reported the synthesis, evaluation and modeling of a 
series of GFP-chromophore inspired arylmethylene-imidazolone as estrogen receptor α ligands. 
Through perturbation of analogues we have been able to determine key criteria for activation of 
this class of ligand to be hydrogen bonding, molecular volume, and molecular topology. 
Establishing a hydrogen bonding relationship between the ligand and the ligand binding pocket 
emerged as the most dominant contributing factor. Without this relationship activation for this 
class of ligand cannot be achieved. Molecular volume and topography are two additional factors 
that fluctuate as attenuation to ligands occur. Molecular volume demonstrated a direct 
relationship with activity we demonstrated for this class of ligand as volume exceeds that of 
estradiol activity diminishes. Through molecular topography we demonstrated that the most 
active of this class of ligand contain polar aromatic cores and small nonpolar substituents.  
Several ligands were found to be active and in agreement with literature described 
pharmacophore, of specific interest CW32 elicited potency 2-fold above that of estradiol. The 
interesting potency of CW32 has prompted binding affinity studies as our next investigation.  
While not as sensitive as estradiol the ability to promote higher activation, levels have intriguing 
potential contraceptive implications like ethynyl estradiol. In agreement with specific aim 2 
focus will now turn on ensuring ligands can promote activation selectively. Testing in ERβ as 
well as other nuclear receptor families is the next step. 
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4.11 Materials and Methods 
 
EXPERIMENTAL SECTION   
 Chemistry  
General 
Estradiol was purchased commercially from Sigma-Aldrich (St. Louis, MO). All AMI ligands 
were synthesized using Baldridge's adaptation of Bazureau protocol [24]. Proton nuclear 
magnetic resonance (1H-NMR) and carbon 13 nuclear magnetic resonance (13C-NMR) were 
recorded on a Varian Mercury 300 nuclear magnetic resonance spectrometer in appropriate 
deuterated solvent (CDCl3 or DMSO), chemical shifts are reported in  units with 
tetramethylsilane (TMS) as an internal standard. Electron spray ionization (ESI) analyses were 
performed on and time of flight (TOF) methodology. Thin layer chromatography (TLC) was 
conducted on pre-coated silica gel plates.  Chromatography was conducted using silica gel unless 
otherwise stated. Spectroscopic data as well as yields and melting points can be found in 
supplementary data. Solvents were used as is unless stated as dry then which solvent was 
distilled over appropriate drying agent and store under nitrogen over molecular sieves.    
General Preparation of Schiff Base (I). To an equivalent of aldehyde was added amine in 
slight excess (1.1 equivalent) with stirring overnight. Reactions were conducted as neat only 
when both reagents were liquid, in instances where either the aldehyde or amine were solid 2mL 
of ethanol was used as a solvent. In most cases after 12-14hrs the product was afforded as a 
white or colored precipitate that was collected via filtration and washed with small amounts of 
cold ethanol. Alternatively, several reactions afforded oils that were concentrated in vacuo 
resulting in nearly quantitative yields.   
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General Synthesis of Imidate (II). In 125mL of ether was suspended potassium carbonate 
(5.5g, 39.8mmol) and glycine methyl ester hydrochloride (4.99g, 39.8mmol). To the suspension 
was added 20mL of water followed by ethyl acetimidate hydrochloride (4.92g, 39.8mmol). The 
mixture was shaking vigorously with venting for 6 minutes followed by decanting of the organic 
layer. An additional 100mL of ether was added and shaken continued further for 6 minutes. The 
organic layers were combined and washed with brine, dried over anhydrous magnesium sulfate; 
and filtered.  The filtrate was concentrated in vacuo to give a clear oil. The imidate was used 
without further purification. The imidate was stored under nitrogen at 0oC for no more than a 
week.  
General Synthesis of Substituted Arylmethyleneimidazolonone (III). To an equivalent of 
Schiff base in 2mL of ethanol was added the previously synthesized imidate (1.02 equivalent) 
and stirred overnight. Precipitation occurred overnight for most reactions and afforded a solid 
that was filtered, washed with cold methanol and dried in vacuo. In the absence of a precipitate, 
the crude reaction was placed at 0oC for 48hrs upon which crystallization occurred. When 
crystallization did not afford product, chromatography was conducted on the crude reaction 
mixture yielding pure product as a solid or oil. 
Preparation of 2,5-dichloro-2,5-dimethyl hexane (IV) 28. To 240mL of reagent grade 
concentrated hydrochloric acid was added 2,5-dimethyl-2,5-hexanediol (15.6g, 106.9mmol) and 
stirred overnight at room temperature. After stirring 500mL of water and 500mL of methylene 
chloride was added to the crude mixture. The organic layer was separated, and the aqueous phase 
extracted with methylene chloride.  The organic layers were combined washed with water; and 
dried with anhydrous magnesium sulfate; and filtered. The filtrate was concentrated in vacuo to 
give a white solid (18.0g, 92%). 
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Preparation of 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphthalene (V) 29. A stirred 
solution of 2,5-dichloro-2,5-dimethyl hexane (2.50g, 13.65mmol) in dry toluene (50mL) was 
cautiously treated with aluminum trichloride (180mg, 1.35mmol) and refluxed under dry 
conditions for 12 hours. After which the crude solution was cooled to room temperature and 
poured over ice. The organic layer was separated and washed with 10% HCl, water, brine, dried 
with anhydrous sodium sulfate and filtered. The filtrate was distilled to remove excess toluene 
and collected as an oil (2.45g, 89%). 1H NMR δ 1.30 (s, 12H, 4CH3),1.69 (s, 4H, CH2CH2) 2.35 
(s, 3H, CH3) 6.99 (d, 1H Ar-H) 7.19 (s, 1H, Ar-H) 7.31 (d, 1H, Ar-H). 
13C NMR δ 21.6, 32.3, 
32.4, 34.3, 34.5, 35.6, 35.7, 126.8, 126.9, 127.3, 135.0, 142.1, 144.9.   
Preparation of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde (VI) 30. 
To a solution of V (4.08g, 20.1 mmol) in 20mL of acetic acid heated to 100oC under vigorous 
stirring was added was added ceric ammonium nitrate (47.54g, 86.7mmol) in 50% acetic acid. 
Dropwise addition was carried out over 2 hours followed by stirring for 2 hours. The crude 
solution was cooled and poured over ice.  The aqueous layer was extracted with petroleum ether, 
washed with water, brine, dried with anhydrous magnesium sulfate; filtered and concentrated in 
vacuo. The crude mixture was purified via column chromatography using 10% ether/hexane as a 
mobile phase. Purification produced (3.3 g, 76 %). 1H NMR δ 1.28 (s, 12H, 4CH3), 1.71 (s, 4H, 
CH2CH2), 7.41 (d, 1H, Ar-H), 7.57 (d, 1H, Ar-H), 7.81 (s, 1H, Ar-H), 9.89 (s, 1H, H-C=O). 
13C 
NMR δ 31.5, 31.7, 34.1, 34.7, 34.7, 34.8, 126.6, 127.3, 128.5, 134.3, 145.7, 152.2, 191.9. 
Chemical Complementation in Yeast 
Conventionally chemical complementation is genetic selection highlighted using a small 
molecule. Herein we use a three-component system linking the survival of yeast to the ability of 
a small molecule modulator to activate nuclear receptor transcription. The yeast strain used 
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(Saccharomyces cerevisiae – PJ69-4A) contains Gal 4 response elements (Gal4RE) used to 
control the expression of genetic selection genes involved in the histidine (HIS3) and adenine 
(ADE2) biosynthetic pathway. Transformed in the yeast are two fusion proteins, a Gal 4 DNA 
binding domain (Gal4DBD) fused to a nuclear receptor ligand binding domain (LBD) and a Gal 
4 activation domain (GAD) fused to a nuclear receptor co-activator (SRC-1). At the core of 
chemical complementation binding of a ligand to the nuclear receptor LBD promotes binding of 
the LBD: Gal4DBD fusion with the Gal4RE thus prompting a conformation change of the 
receptor allowing for recruitment of the GAD:SRC-1 fusion. Completion of this cascade actuates 
transcription of selective genes (HIS3 or ADE2) thereby allowing yeast to survive in media 
lacking the presence of histidine or adenine. (Fig.3). Yeast trans formant (pGBDhERαLBD) was 
grown overnight in 2mL of media lacking leucine and tryptophan (SC-LW) at 30°C with shaking 
at 300rpm. After growth, yeast was pelleted (4°C, 7min, 3700rpm,) media discarded and re-
suspended in 1mL of water. A second pellet was formed and re-suspend in 1ml of water before a 
45µL aliquot was added to 5mL of water. Media lacking histidine, leucine and tryptophan (SC-
HLW with 0.1mM 3AT) was prepared and ligand-media mixes were made via dilutions from 
pre-made ligand stock solutions (10-2 M) with a final concentration of 10µM.  The incorporation 
of 3AT (0.1mM) was necessary to suppress background arising from imidazole glycerol-
phosphate dehydratase a key enzyme in the histidine biosynthetic pathway. In the case of dose 
responses serial dilutions were performed starting with 10 µM, solutions ranged from (10-5M-10-
12M). Using a multi-channel pipetor 20µL of cells were added to 80µL of ligand in a 96 well 
plate. To wells not containing cell: ligand mix, 80µL of water was added. Plates were incubated 
48hrs (30°C and 300rpm) with optical density (OD) measurements recorded at 0, 24, 48-hour 
intervals. Optical density readings were taken at a wavelength of 630 nm.   
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Mammalian Cell Culture Assay 
Human embryonic kidney 293T (HEK293T) cells (ATCC, USA) were transfected with the 
plasmid pCMXwithERαLBD.  This plasmid contains the Gal4DBD (GBD) fused to the wild-
type ERα ligand binding domain LBD (GBD: LBD fusion under the control of a 
cytomegalovirus (CMV) promoter).  The reporter plasmid, p17*4TATAluc, contained the 
Renilla luciferase gene under the control of four Gal4 response elements located upstream from a 
minimal thymidine kinase promoter. The pCMXβgal, a plasmid containing the β-galactosidase 
gene under the control of the mammalian CMV promoter, was also used as an internal standard. 
Lipofectamine 2000 (Invitrogen, USA) was used as the cationic lipid and transfection 
experimental details are described in Taylor et al.  Ligands were added to the wells at various 
concentrations.  Cells were harvested 48hrs after the addition of ligand and analyzed for 
luciferase and β-galactosidase activity.  All data points represent the average of triplicate 
experiments normalized against β-galactosidase activity, standard deviations are represented 
using error bars.   
 In Silico Docking Studies 
 Modeling of ligand-receptor complexes were carried out using AutoDock Vina® [36]. The 
crystal structure of human estrogen receptor α (PDB ID: 1ERE) [26] was obtained from the 
research collaborator for structural bioinformatics (RCSB) protein data bank (PDB).  Ligands 
were created in ChemBioDraw Ultra 13.0 transferred to ChemBio3D Ultra where they were 
minimized using MMFF84 force field and saved as pdb files. Ligands were modified with Auto 
Dock Tools by adding Gasteiger charges to set the partial charge of each atom and hydrogens on 
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CHAPTER 5  
INVESTIGATING SELECTIVITY WITHIN ESTROGEN RECEPTOR β 
AND THE NUCLEAR RECEPTOR FAMILY 
 
 
 The emergence of an additional subtype of the estrogen receptor, ERβ altered the lens through 
which estrogen regulation had been viewed. Encoded by a different gene than that of its 
predecessor, ERβ was cloned in 1996 from rat ovary and prostate [1]. ERβ can often be found 
expressed in identical systems, tissues and cells as that of ERα with variation in the ratio of 
expression levels [2]. Like other nuclear receptors ERβ possess the ability to mediate a 
physiological response in reply to the presence of a ligand. The coexistence of both subtypes in 
identical tissues and the ability to bind similar compounds facilitated the need of ligands that can 
be selective in receptor subtype, tissue and response (agonist vs antagonist) profile. These 
ligands are termed selective estrogen receptor modulators or SERM’s [3]. This class of 
compound is characterized by their ability to promote different behavior in varying tissues i.e. 
antagonist in mammary but agonist in ovary. The generation of ligands that can be classified as 
SERM’s are of extreme importance, the ability to facilitate binding leading to activation or 
repression in a discriminatory fashion may prove instrumental in minimizing unwanted side 
effects. In an effort to answer the question is binding and activation observed in chapter 4 
restricted to ERα active, ligands were screened against ERβ. Additionally the previously 
synthesized library of GFP inspired ligands was included in ERβ screening for discovery of 




5.1 Estrogen Receptor β 
 
The regions and domains of ERβ remain the same as traditional nuclear receptors as described in 
Chapter 3. Though the domains have the same function, the role of AF-1 in transcription with 
ERβ is weaker compared to that of ERα, therefore recruitment of transcriptional machinery is 
heavily dependent upon AF-2 [4]. Structurally at 530 amino acids ERβ is smaller than ERα while 
fewer amino acids are present ERβ maintains 44% sequence homology, with higher 
conservations located within specific regions AF-1 (16%), DBD (96%) and LBD (59%) [5,6].   
In addition to locations such as cardiovascular system [7], breast tissue and reproductive organs 
where both subtypes can be located, ERβ can be found exclusively within the colon, lungs, 
prostate, bladder, gastrointestinal tract and in higher expression levels in ovaries, bones, vascular 
epithelium and regions of the brain.  [5]. The wide spread cellular distribution of ERβ identifies 
the need for ligand development that is deliberate and careful thus a critical comprehension of 
targeting the ligand binding pocket is a must.    
 5.1.1 Ligand Binding Pocket  
 
The ligand binding pocket serves as the processing center for ligand-receptor interactions. The 
mainly hydrophobic pocket has two defining characteristics the volume of the pocket and the 
amino acid residues that make up the lining of the pocket. Physically the ERβ ligand binding 
pocket is 375A3 [8] about 100 angstroms smaller than ERα. Lining the available space of the 
pocket are a series of amino acids residues reminiscent of ERα. Key residues in ERβ ligand 
binding pocket include His-475, Gln-305, Arg-346 analogous to essential residues His-524, Gln-
353 and Arg-394 in ERα. Comparative analysis between the ligand binding pocket of the two 
subtypes reveals that only a two residue substitutions exist, Leu-384 and Met-421 in ERα are 
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converted to Met-336 to Ile-373 respectively in ERβ [8]. The presence of similar LBP residues 
and an established hydrogen bonding network identical to ERα facilitates concern that active 
ligands may also bind ERβ. The lack of large divergence within the ligand binding pocket makes 
examining the profile of activating ligands important to begin to discern features that may 
contribute to selectivity.  
Figure 5.1 Estrogen receptor β secondary structure with ligand binding pocket inset. Structure of 
ERβ predominately helices(red) and loops (green). Inset shows mesh ligand binding domain with 




The generic estrogen receptor pharmacophore established by Katzenebollgen [8] holds true for 
both receptor subtypes therefore ligands such as estradiol activate ERβ in addition to ERα mainly 
due to the similarity of residues within the pocket therefore similar features will be deemed 
necessary to promote binding. In addition to binding estradiol with high affinity, [6,9] ERβ can 
also bind other natural as well as synthetic ligands bound by its counterpart for instance 4-
hydroxytamoxifen. Binding of 4-hydroxytamoxifen to ERβ demonstrates pure antagonist 
behavior where as in certain tissues possessing ERα partial agonist profile is exhibited [7] the 
variation in behavior is accredited to diversity in pocket size.  
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Like its predecessor ERβ can bind a diverse series of ligands that share small commonalities 
such as genistein, liquiritigenin, S-equol and the notable 4-hydroxy tamoxifen. The capability of 
ERβ to bind ligands like that of ERα, challenges the ability to generate ligands that are selective 
binders. Most ligands for ERβ contain an ACD ring system analogous to ERα ligands including 
our GFP inspired chromophore ligands. Though equivalent in ring system diversity in the core is 
implicated as one of the major pathways to achieving selectivity.  
 
Figure 5.2 Known estrogen receptor β agonist. The above compounds are all known agonist for 
estrogen receptor β. While diverse structural commonalities can be identified through the use of 
phenol moieties and multiple aromatic cyclic systems.  
 
5.1.2.1 Selective Ligands 
Starting with Katzenebollgen’s ER pharmacophore a more specific ERβ selective 




Figure 5.3 Estrogen Receptor β selective pharmacophore. The above pharmacophore was 
designed to generate isotype selective ligands. 
 
pharmacophore is the fusion of the phenol ring with the central core. The core can serve as a 
focal point for selectivity due to the residue that sits above it. Of the two non-conserved residues 
Met-336 is located above where the C ring rest in ERβ binding pocket [11]. Though the 
conversion of Leu-384 to Met-336 is conservative in polarity, sterically the residues occupy 
different volumes [12]. The Met-336 residue allows for less steric hinderance than the Leu-384 
(ERα) causing ERβ to forgo the linker space found in ERα pharmacophore. Using this model, a 
wide variety of agonist have been generated showing binding and selectivity with varying fused 
cores such as indazoles, benzothiophenes, benzofurans, indenes, phthalimides, indoles, 
imidazoles, naphthalene and quinoline [11]. While the selective pharmacophore embraced 
categories of compounds that were structurally different from our AMI class of ligands one 
certain group was of interest the arylindenones. Similar in structure to that of the AMI ligands, 2-
Arylindene-1-ones overall showed lower ERβ selectivity however some showed good binding 
affinities for that of ERβ [13] The reported ERβ binding affinity for 2-arylindene-1-ones was 
attributed to the ability to maintain a hydrogen bonding network and the ligands size, both of 




Figure 5.4 Core structures used in estrogen receptor β ligands. The above exemplifies the 
diversity in cores that can be used with generating ERβ ligands.  
5.1.3 Physiological Role of ERβ 
 
The physiological function of ERβ is much different from that of ERα with ERβ often directly 
counteracting the effects of ERα [14.]. Gene regulation of ERβ commonly leads to fluctuation of 
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cell cycle progression and apoptosis [15] which is opposite of its counterpart were activation 
typically promotes cell proliferation. Correlation between the loss of expression of ERβ has been 
well documented with breast, ovarian, and colon cancers where the progression of the cancer has 
been accompanied by suppression of ERβ [16] even completely absent in some cancers in more 
mature stages. Tumor suppression with higher levels of ERβ expression is suggestive that 
physiologically ERβ exerts a protective role against cancer development. The restraining ability 
of ERβ over its subtype counterpart has generated pharmaceutical interest for ligands that 
demonstrate specificity in activation. Exploitation of the physiological features of ERβ has been 
employed in exclusive targeting of the subtype in early stage of breast and colorectal cancers 
[17], however the complication resides in selective subtype agonist targeting and varying ratios 
of α/β expression. The presence of dual subtypes with opposing physiological response, varying 
distribution and expression levels underline both the need and complexity of ensuring that our 
designed ERα active ligands are target selective and function specific.        
5.2 Design for Isotype Selectivity 
 
Designing ligands with the capabilities to distinguish sites within the same class of nuclear 
receptor typically involves exploiting the differences between the target sites. While this 
approach can be used for designing ligands that are receptor family specific the strategy becomes 
more complex when selectively targeting subtypes such as ERβ vs ERα. In the case of these two 
subtypes the sole diverging features were the narrower pocket with smaller volume and the two 
differing residues in the pocket. Driven by our initial results of agonist binders we wanted to 
explore the influence of the ACD ring system and the pockets volume. Lastly, we wanted to 





As outlined in chapter 4 our chosen core promoted an ACD ring system in addition to agreeing 
with the GFP chromophore structure the ring system agreed with the proposed nonselective 
estrogen receptor pharmacophore. Interestingly the proposed pharmacophore for subtype beta 
also encourages an ACD ring system.      
 
Figure 5.5 ACD ring system for both estrogen receptor selective and non-selective 
pharmacophore. Both pharmacophores utilize a ACD ring system like the GFP inspired ligand.  
5.2.2 Chirality 
 
Visual inspection of several estrogen receptor ligands identifies the presence of a stereocenter in 





Figure 5.6 Estrogen receptor β ligands possessing chiral centers. The above ligands all bind ERβ 
and they all pose chiral centers in key locations that effect ligand-receptor interactions. 
Natural ligands exist for ERβ that are selective or show preference such as S-equol [18] or17β-
estradiol [19] and house a stereocenter that displays facial preference. The most commonly noted 
example of selectivity as a function of chirality is with the diarylpropionitrile or DPN 
enantiomers [20]. Of the two enantiomers the S-configuration possess the higher potency and 
selectivity for ERβ, the successful turn-on of transcription is also solely located in the S-
configuration [21]. The variation in activity is attributed to the influence the stereocenter has on 
positioning the cyano group in contact with specific residues [22]. Exploration into the role that 
chirality could potentially play in our ligands promoted the synthesis of an additional set of AMI 
ligands. This 3rd generation of ligands were designed using A-rings with the hydroxyl in the para 
position and ortho position like the cores of CW34 and CW32 respectively as well as the 2,4-diol 
phenol seen in CW63. As illustrated in the figure below at the front of the ligand we incorporated 
a stereocenter bearing a hydroxyl group while maintaining a propyl chain. The importance of the 
hydroxyl group was to facilitate hydrogen bond acceptor interaction with the pocket but to see if 
a facial preference existed. The rationale for maintaining the propyl chain was to stay in 
compliance with ERα binding achieved. In the previous chapter we demonstrated that the 
presence of the small nonpolar substituent in front is beneficiary to ERα binding. Ideally 
incorporation of a stereo-center would promote selectivity by enhancing favorable residue 
contacts for ERα while minimizing access to key ERβ activating residues through establishing 




Figure 5.7 GFP inspired ligands generated to explore chirality. Ligands containing a chiral center 
were designed using template of the most active activator CW32. 
 
5.3 Chemical Complementation 
 
The same chemical complementation method was employed for the screening of ERβ with the 
difference being the use of ERβLBD:Gal4DBD fusion as opposed to ERα. 
5.3.1 Estrogen Receptor α active ligands 
 
The conservation of residues within the ligand binding domain of ERα and ERβ result in 
nondiscrimination of a vast number of ligands. In addition to ligands that produced a response, 
ligands of similar substitutions were also screened in hopes of possibly discovering a lead for the 
same class of ligands that consequently only activate ERβ. Although ultimately all compounds 
were screened against ERβ of primary interest was molecules that showed activity in ERα 
assays.  Once again growth was observed for CW32 only. Optical density levels for CW32 were 
observed at 0.60 ± 0.05. Identical controls were employed with NL demonstrating an OD of 0.04 
± 0.02 and estradiol an OD of 0.48 ± 0.01, in addition the same positive control (Gal 4) was used 
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expressing OD values around 0.61 ± 0.1. The reduced optical density value of CW32 in ERβ 
may imply that a slight preference for ERα is possible like the profile of estradiol with ERα and 
ERβ. Overall, activation as observed via chemical complementation for selective estrogen 
receptor activation indicates that CW32 activates both ERα and ERβ subtypes however possibly 
with slight partiality. 
Table 5.1 Estrogen receptor β chemical complementation. 
Ligands Optical Density 
CW32 0.60 ± 0.1 
Ethynyl Estradiol (EE2) 0.50 ± 0.3 
Estradiol (E2) 0.48 ± 0.01 
Gal 4 (positive control) 0.63 ± 0.1 
No Ligand (NL) 0.04 ± 0.02 
 
 
5.3.2 AMI Library Screen  
 
In addition to the ERα active ligands the remainder of the compounds generated through out 1st 
and 2nd generation synthesis was screened. No additional ligands from these two generations 
produced results that would be considered significant. Chemical complementation screening of 
AMI library resulted in no observation of activation for ERβ.  
5.3.3 Generation III Results (Chiral AMI Ligands) 
 
Arylmethylene imidazolone ligands containing a chiral center were screened as third generation 
ligands exploring chirality. Since the incorporation of a chiral center did not occur until 
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investigation of receptor subtype selectivity third generation ligands were screened for activity in 
ERα as well as ERβ. Like screening of previous generation controls included the no ligand (NL) 
vehicle, Gal 4 and estradiol. No growth was observed in the NL yielding an OD of 0.04 ± 0.01, 
positive controls Gal4 and estradiol gave an OD’s of 0.665 ± 0.2 and 0.454 ± 0.1 respectively. 
Chemical complementation screening of 3rd generation ligands resulted in no observation of 
activation.    
5.4 Luciferin Reporter Assay Analysis for Isotype Specificity 
 
Using the same methodology employed for ERα screening, the LBD of ERβ was fused to Gal4 
DBD and transformed into pCMX mammalian vector. Identical to ERα analysis compounds 
were screened in HEK293T cells and estradiol was employed as a positive control. It is 
important to note here that estradiol exhibits a preference for ERα over that of ERβ here go it is 
expected that observed control values for ERβ will be lower. Estradiol’s observable accepted 
value for our ERβ analysis is 14 ± 0.2 as opposed to 26 ± 0.7 in ERα. 
5.4.1 Estrogen Receptor α Active Ligands 
 
Initial screening was conducted to assess compounds that have shown activation in ERα. Of the 
set of activators CW32 displayed considerable activation above baseline 6.4 ± 0.3 almost half 
that of estradiol. Results indicate that ERβ activation for CW32 is far less sensitive to small 
structural modifications than that of its counterpart. Rotation of the phenol from the ortho 
position to the para position CW28 results in loss of activity with a reading just above baseline at 
2.5 ±0.04. Likewise, alteration of the amide substituent from isopropyl to propyl CW32 and 
CW30 also resulted in loss of all activity 1.6 ± 0.1. Abolishment of activity was also observed 
with CW35 and CW38 wherein the isopropyl group was converted to cyclopentyl and 
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cyclohexyl rings yielding results of 2.0 ± 0.2 and 2.0 ± 0.24 respectively. Of the compounds 
initially designed to assess the role of hydrogen bonding in the front of the pocket only CW34 
showed activity above the baseline at 2.8 ± 0.02 roughly a third that of CW32. The results from 
the remainder of the ligands can be viewed in table 5.8  
 
Figure 5.8 Screening of ERα active ligands against ERβ. Ligands shown to be active in ERα 
were tested against ERβ for selectivity. 
 
Table 5.2 Results of ERα active ligands screened against ERβ. 
Ligands Fold Induction 
CW28 2.5 ± 0.04 
CW29 2.4 ± 0.1 
CW30 1.6 ± 0.04 
CW32 6.4 ± 0.3 
CW34 2.8 ± 0.3 
CW35 2.0 ± 0.2 
CW38 2.0 ± 0.2 
CW39 2.7 ± 0.6 
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CW61 2.0 ± 0.9 
CW63 1.9 ± 0.3 
CW72 1.8 ± 0.1 
Estradiol (E2) 14 ± 0.2 
No Ligand (NL) 1 
 
5.4.2 AMI Library Screen 
 
In addition to the ERα active ligands the remainder of the compounds generated through out 1st 
and 2nd generation synthesis was screened. No additional ligands from these two generations 
produced results that would be considered significant.   
5.4.3 Generation III Results 
 
Chiral ligands were screened including the racemate and the separate enatiomers, as stated 
previously these ligands were not generated during the initial ERα screen therefore in addition to 
ERβ, ligands were screened against ERα as well. Surprisingly no 3rd generation ligands produced 
activation higher than that of baseline for ERα or ERβ. Worth considerable mention are the 
results of CW86 in ERβ in comparison with the same ligand in ERα. While CW86 produced 
normal baseline activity in ERα (1.5 ± 0.3) with ERβ baseline activity suppressed with a reading 
of 0.87 ± 0.03. While exploration into estrogen receptor subtype selective antagonist is beyond 
the motivation of this dissertation this compound may prove as a starting point for future work. 
Also, worth noting is ligand CW98 that showed response slightly above that of baseline for ERα 
(2.7 ± 0.1) and a normal baseline for ERβ (1.5 ± 0.2).   
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5.5 Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) 
 
This assay employs estrogen receptor α and β labeled via a GST tag bound to its anti-GST 
antibody that is terbium labeled. Competitive binding to estrogen receptor occurs via our AMI 
agonist ability to displace a fluorescent ligand in our case fluorescently labeled estradiol (ES2 
Green tracer). The proximity of labeled ligand and the tagged antibody directly corresponds to 
the strength of the FRET signal [23]. Here successful displacement of the tracer by our AMI 
agonist will result in a decrease in FRET signal. This experiment was conducted to strengthen 
our hypothesis that all binding observed by our agonist occurred in the same pocket as that of 
estradiol and not via any alternative binding site. This experiment was also carried out to support 
the result of ERβ screening which demonstrated preference for subtype with select ERα active 
agonist. A subset of four compounds were chosen to be tested in ERα and ERβ. The compounds 
selected included the highest two activators CW32 and CW34 as well as the lowest activator 
CW72, lastly as a negative control CW33 was used which had proven to be a non-binder in all 
assays. As shown in the charts below our highest two activating compounds displace estradiol in 
both ERα and ERβ, however both with preference to ERα. While the lowest activator in our 
assay agonist CW72 exclusively displaced estradiol in ERα and displayed no displacement in 
ERβ. Table 5.3 list displacement percentages of tested compounds for both estrogen receptor 




Figure 5.9 TFRET dose response curve for select GFP-inspired ligands. Select ligands were 
chosen (top 2 activators, lowest activator and a non-activator) and assayed via TFERT assay the 
10pt titration curve for both isotypes are illustrated.  
 
Table 5.3 Percentage of estradiol displaced by select GFP-inspired estrogen receptor agonist. 
Select ligands were chosen (top 2 activators, lowest activator and a non-activator) and assayed 
via TRFRET assay the percentages of the displaced tagged indigenous ligand are listed for both 
isotypes.  
Ligands ERα ERβ 
CW32 89% 55% 
CW34 75% 24% 
CW72 37% 0% 




5.6 Selective Ligand Activation Discussion Rationale ERβ 
 
As stated previously differential targeting in the ligand binding pocket between ERα and ERβ 
can be complex due to only two substitutions in amino acid residues within the pocket. While the 
variation in pocket size contributes to ligand selectivity certain factors are still necessary for 
successful binding within the pocket. These criteria are the same as what we established in the 
designing of our ligands recall attention was given to: 1) preservation of hydrogen bonding 
network via key amino acid residues within the ligand binding pocket 2) size and volume 
occupied by the ligand and lastly 3) molecular landscape of the ligand with respect to polarity 
therefore, analysis of results from ERβ was developed from the above criteria and explained 
through those guides.   
5.6.1 Hydrogen Bonding Network  
With key residues such as arginine, glutamic acid, and histidine unchanged within the ligand 
binding pocket the opportunity for ligands to participate in a network of hydrogen bonding with 
the receptor is parallel to that of its counterpart.  
 
Figure 5.10 Hydrogen bonding network within estrogen receptor β ligand binding pocket. Key 
residues shown as sticks involved in hydrogen bonding network with selective agonist genistein 




The preservation of the hydrogen bonding network is exemplified through Richardson etal. 
studies on benzopyrans as selective estrogen receptor β agonist or SERBA [24-27]. In the case of 
the benzopyrans the incorporation of two phenols located at the ends of the ligand analogous to 
A and D rings in estradiol resulted in water assisted hydrogen bonding with Gln-305, Arg-346 
and direct hydrogen bonding with His-475. Ligand modeling in chapter 4 illustrated that our 
ERα active ligands participate in hydrogen bonding either with the 3 key residues or with the 
carbonyl backbone in amino acid residues. As illustrated in figure 5.10 the same opportunities 
exist with ERβ. Figure 5.11 shows a significant increase in the distance of ligand and amino acid 
residues involved in hydrogen bonding. 
  
         
Figure 5.11 Hydrogen bonding network within ERβ. A) Genistein (shown in middle) participates 
in hydrogen bonding with all 3 key residues as illustrated all with a distance under 4A (shown as 
dashed lines in black). B) CW34 can hydrogen bond with all 3 key residues however distances 





distances as shown with black dashes exceed that of 4A. D) CW32 only interacts with Gln-305 
however does not interact with the other 2 key residues. 
  
The large distance suggest that hydrogen bonding is not likely to occur even if it were water 
mediated. CW32 while it does not interact with all 3 key residues in the ligand binding pocket it 
does participate in hydrogen bonding relationship with Gln-305 and is under 4 A distance. It 
appears the main reason successful hydrogen bonding is not achieved is due to the placement of 
the ligand in relation to the LBP of ERβ. In comparison to its predecessor where the priority was 
centered around the ability to participate in a hydrogen bonding network it appears here priority 
must be given to ligand volume to ensure additional criteria can be supported.  
5.6.2 Ligand Volume-Size Shape 
 
The smaller size of ERβ ligand binding pocket is the most distinguishing difference of the two 
binding pockets and pose possibly the greatest restrictor on selectivity and activation. Activators 
of ERα that are considered rather large such as the tetra substituted propylpyrazole (PPT) or the 
triarylamide’s are excellent agonist for ERα however display minimal affinity for ERβ. 
Comparisons of molecular volumes of several known ERβ agonist with select AMI ligands are 
illustrated in Table 5.4 indicate relatively comparable size.  
Table 5.4 Molecular volume and selectivity for known estrogen receptor β ligands and GFP 





DPN 222 ERβ 
Genistein 272 ERβ 
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Benzoxazole 226 ERβ 
Isocoumarin 233 ERβ 
Isobutestrol 222 ERβ 
CW32 230 ERα 
CW33 222 Neither  
CW34 259 ERα 
 
While the volume of both CW32 and CW34 are well within the limits of acceptable agonist such 
as genistein and highly selective DPN; CW34 and CW32 orientation within the ligand bonding 
pocket of ERβ presumably contributes to its preference for ERα. As molded in figure 5.12 
genistein is oriented within the pocket however the majority of the GFP inspired ligands do not 
align with in the pocket, CW34 even appears to be larger than the binding pocket.  





Figure 5.12 Modeling of volumetric space of Estrogen receptor β ligand binding pocket and 
select ligands. A) Genistein shown as a sphere inside of the estrogen receptor ligand binding 
pocket shown in mesh. B) CW28 shown as spheres sits slightly under the ligand binding pocket 
with portion of the ligand in the pocket (mesh). C) CW34 shown as spheres indicates that only 
the middle of the ligand sits inside of the ligand binding pocket (mesh) while the remainder of 
the ligand rest outside the pocket.      
Activators of ERβ tend to be slenderer to accommodate the smaller sized pocket, ligands such as 
diarylpropionitrile (DPN) and isobutestrol exemplify this. Studies show that as size of the ligand 
increases activation may increase however selectivity diminishes [28]. In the case of ligand 
CW32 modeling indicates that the ligand does not exist within the ligand binding pocket 
however resides just to the left in what appears to be a secondary pocket as shown in figure 5.13 
below.  
                
Figure 5.13 Placement of CW32 in secondary pocket within ERβ. A) CW32 shown as yellow 





yellow spheres resting in an additional binding pocket while genistein shown as spheres resides 
in the ligand binding pocket.  
 
5.6.3 Molecular Topology 
 
Though drastically similar in amino acid residue the molecular surface area of the ligand can 
have a large impact on binding and activation. Ligands that are known to be selective or potent 
for estrogen receptor β were computationally calculated to have varying polar surface areas 
suggesting that ERβ ligand binding pocket is tolerant of diverse polarity within ligands. Table 
5.5 below list various AMI ligands with varying cores in comparison to known binders. In 
addition to the polar surface area of the ligand the landscape of the ligand binding domain is 
important as well. Analysis of table 5.5 indicates that while polar surface area may be a criterion 
adhered to for overall estrogen receptor binding and activation it does not appear to have bearing 
on selectivity. 
Table 5.5 Polar surface area of select AMI ligands and ERβ selective ligands. 














The incorporation of a chiral center to enhance selectivity for estrogen receptor α did not prove 
to be useful as the ligands possessing chirality were not active.   
 
5.7 Identification of Active Leads for Estrogen Receptor 
 
Summation of chemical complementation and luciferin reporter gene assay results revealed a 
series of substituted arylmethyleneimidazolones that are viable as nuclear receptor binders. 
Further exploration demonstrated that several of these analogues serve as estrogen receptor 
agonist bearing specificity or strong preference for subtype α as opposed to β. While analogues 
CW72 was completely exclusive for estrogen receptor α others such as CW32 exhibited 
activation in both isotypes α and β however displayed a preference for ERα. Activation intensity 
varied from levels well below estradiol, to comparable and even exceeding estradiol. The robust 
number of compounds synthesized and evaluated allowed for creation of a suitable structure 
activity relationship analysis which can be fitted to known activation rationale parameters.  
The generation of several estrogen receptor agonist along with identification of subtype 
preference prompted the next aim, investigating selectivity on a boarder scale to ensure that 
activating compounds were nuclear receptor selective otherwise known as SNuRM.  Progressing 
forward only compounds listed as estrogen receptor α binders (Chapter 4) resulting in agonist 







5.8 Nuclear Receptor Selectivity 
 
The presence of additional families of nuclear receptors in the body creates alternative 
opportunities for binding of ligands. Nuclear receptors domains are held constant however 
diversity is demonstrated largely across families especially within the ligand binding domain and 
even more in the ligand binding pocket however it is possible for ligands that activate one family 
to possess favorable properties for another. While this may seem like a positive side effect 
specifically for receptors that work in concert where activation or repression of both yield an 
enhanced desired outcome it can be disastrous for receptors that turn on unwanted physiological 
responses linked to diseases. This rationale prompted the screening of only active ligands to 
ensure that selectivity can be observed across nuclear receptors with the implication more 
selective ligands should produce minimal undesired side effects. Chemical complementation 
screening as outlined in chapter 4 was employed in assessment of compounds identified as 
agonist for estrogen receptor α. Both retinoic acid receptor γ (RARγ) and rexinoid x receptor α 
(RXRα) ligand binding domain where used in place of estrogen receptors ligand binding domain.    
5.8.1 Rexinoid X Receptor α 
 
Rexinoid X Receptor (RXR) is an intriguing player within the nuclear receptor family while 
debate exist as to the physiological role of the receptor, RXR is highly coveted for its ability to 
form heterodimers with other nuclear receptors. Partners for the RXR heterodimerization include 
LXRα, PPARα, CARβ, PXR and FXR all of which have been reported that in the absence of the 
ability to heterodimerize with RXR the physiological pathways controlled by those receptors are 
compromised [29]. Heterodimers generated by RXR exist as one of two categories either 
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permissive such as PPAR, LXR, PXR or non-permissive such as RAR, VDR, TR [30, 31]. The 
distinction between the two categories are that for permissive partners binding of an RXR ligand 
co-promotes ligand binding of the partner receptor while in non-permissive heterodimer pairs 
RXR serves as a silent partner primarily functioning to assist in binding of the hormone response 
element. With the ability to form combinatorial partners with one third of the 48 human nuclear 
receptors RXR represents an alternative to activating multiple signaling pathways and an 
important receptor to ensure that non-targeted RXR ligands do not activate.  
Rexinoid x receptor exist in three isotypes α, β, γ attention in literature has been given to RXRα 
[32] therefore focus for selectivity will center on RXRα. Isotype RXRα is abundantly expressed 
in the liver, kidney, spleen and placenta epidermis as well as a variety of visceral tissues [33,34]. 
Reminiscent of the role over expression of ERα plays in breast cancer, over expression of RXRα 
has been reported in 66% of breast ductal carcinomas [35]. Structurally composed of 462 amino 
acid residues it is smaller than that of ERα [34]. The LBD is composed of the common three-
layered alpha-helical sandwich and at 238 amino acid residues it is less than 20 amino acid 
residues smaller than ERα LBD (253).     
5.8.1.1 Ligand Binding Pocket Comparison 
 
Through a comparative analysis of the ligand binding pocket of RXRα with that of ERα a clear 
understanding of how to promote selectivity in binding can be obtained. Architecturally the 
ligand binding pocket of RXRα is 400-500A [34] comparable to the volume of ERα (450A). 
With such comparable volumes spatially, ligands that can accommodate ERα ideally can fit into 
RXRα LBP as well. Comparing the type of amino acid residues that reside within both pocket as 
shown in figure 5.14 RXR ligand binding pocket does poses amino acid residues arginine, 




Figure 5.14 RXRα ligand binding pocket complexed with 9-cis retinoic acid. The LBP of RXRα 
different from ERα however contains key residues Histidine, Arginine and Glutamine that can 
establish a hydrogen bonding network.  
 
While the ligand binding pocket of ERα and RXRα host diverse ligands in structure lithocholic 
acid an agonist for RXRα contains the same ABCD skeletal ring system as that of estradiol the 
LBP can also accommodate ABD ring systems figure 5.15. Of even more significant 
commonality are the use of the hydroxyl moiety on the A-ring and the hydrogen bond donating 
carboxylic acid on the D-ring recall both of which advocate binding in ERα. Given these 
overlaps consideration must be given to the possibility that estrogen receptors pharmacophore 




Figure 5.15 RXRα binders with similar ring systems and functionalities as ERα agonist. Ligands capable 
of binding RXR are illustrated with ring system (blue) favorable for ERα. In the case of lithocholic acid 
favorable functionality (red) is present as well. The structural of estradiol ring system (blue) and 
functionality (red) is presented for comparison. 
5.8.1.2 Rexinoid X Receptor Chemical Complementation Results.  
Active estrogen receptor AMI ligands based on the summation of aim 1 were evaluated for 
activation of rexinoid x receptor using chemical complementation. The experimentation used 9-
cis retinoic acid as the positive control ligand and exhibited an optical density (OD) of 0.3 ± 
0.04. Controls in the form of no ligand (NL), and Gal 4 identical to previous chemical 
complementation screening were employed. No growth was observed in the NL yielding an OD 
of 0.04 ± 0.01 and the positive control Gal4 gave an OD of 0.5 ± 0.1. Chemical complementation 




Figure 5.16 Chemical complementation of ER active ligands against RXRα.  Chart above 
indicates activation in only 9-cis retinoic acid (control). 
 
5.8.2 Retinoic Acid Receptor γ 
 
Retinoic Acid Receptors or RAR chiefly forms heterodimers with RXR as the partner however 
ligand mediated activation is achieved through the binding of RAR [30]. Focus on retinoid 
ligand development has led to several approved drugs for this family of receptors coming to 
market. Occurring in three isotypes α, β, γ priority was assigned to RARγ as it is the most 
divergent of the isotypes [36]. Composed of 454 amino acid residues RARγ is smaller in size 
than ERα however the implications of the RAR family in cellular differentiation, proliferation 
and apoptosis outlines a role in cancer like that of estrogen receptors [37]. Specifically, in skin 
cancer RARγ is a predominate player and has 90% expression in epidermis studies have 
indicated that decrease in the levels of expression coincides with tumor progression [38].  
5.8.2.1 Ligand Binding Pocket Comparison 
 
Comparison of LBP for RARγ and ERα display distinct difference. The largest contrast being the 
presence of residues necessary to establish a hydrogen bonding network akin to ERα. As 
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illustrated in figure 5.17 of RARγ LBP coupled with 9-cisretionic acid, an arginine residue is 
present however histidine and glutamine are not. It is worth noting that a serine residue is present 
and capable of hydrogen bonding. The LBP of RARγ has been described as a I-shaped pocket 
with a bulge accommodating ligands with larger steric bulk [30] this contrast in pocket spacing 
could aide in selective ligand recognition.  
 
Figure 5.17 Ligand binding pocket of RARγ. Key residues of RARγ ligand binding pocket 
(sticks) are illustrated with its interactions to 9-cis retinoic acid (green sticks). 
 
5.8.2.2 Chemical Complementation Results 
Active estrogen receptor AMI ligands based on the summation of aim 1 were evaluated for 
activation of retinoic acid receptor γ using chemical complementation. The experimentation used 
all-trans retinoic acid as the positive control ligand and exhibited an optical density (OD) of 0.36 
± 0.1. Controls in the form of vehicle (ethanol:dmso), no ligand (NL), and Gal 4  identical to 
previous chemical complementation screening were employed. No growth was observed in the 
NL yielding an OD of 0.04 ± 0.02 and the positive control Gal4 gave an OD of 0.6 ± 0.2 
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Chemical complementation screening of active ligands resulted in no observation of activation 
from any test ligands. 
   
Figure 5.18 Chemical complementation for estrogen receptor active compounds against RARγ. 
Control all trans retinoic acid was the only compound that displayed activation.  
 
5.9 SUMMARY 
The combination of nuclear receptors ability to exist as isotypes and bind similar classes of 
ligands emphasis the importance of developing ligands that are both isotype and nuclear receptor 
selective. Here in we have demonstrated that a select set of ligands shown to be active in ERα 
can be selective for its isotype ERβ and in the case of CW72 can be exclusive. The highest two 
activating ligands CW32 and CW34 demonstrate good disparity in preference for ERα over that 
of ERβ. Through modeling the rationale for selectivity can be rooted in the absence of hydrogen 
bonding and improper orientation in the ligand binding pocket not satisfying two of the three 
criteria by which the ligands designed centered around. The introduction of a chiral center to 
influence molecular topology proved to be unsuccessful. While ERα ligands exhibited isotype 
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preference globally the ligands displayed nuclear receptor selectivity demonstrating no activation 
in RXRα or RARγ.      
  
5.10 Materials and Methods 
 
Chemical Complementation in Yeast 
Conventionally chemical complementation is genetic selection highlighted by the use of a small 
molecule. Herein we use a three-component system linking the survival of yeast to the ability of 
a small molecule modulator to activate nuclear receptor transcription. The yeast strain used 
(Saccharomyces cerevisiae – PJ69-4A) contains Gal 4 response elements (Gal4RE) used to 
control the expression of genetic selection genes involved in the histidine (HIS3) and adenine 
(ADE2) biosynthetic pathway. Transformed in the yeast are two fusion proteins, a Gal 4 DNA 
binding domain (Gal4DBD) fused to a nuclear receptor ligand binding domain (LBD) and a Gal 
4 activation domain (GAD) fused to a nuclear receptor co-activator (SRC-1). At the core of 
chemical complementation binding of a ligand to the nuclear receptor LBD promotes binding of 
the LBD: Gal4DBD fusion with the Gal4RE thus prompting a conformation change of the 
receptor allowing for recruitment of the GAD:SRC-1 fusion. Completion of this cascade actuates 
transcription of selective genes (HIS3 or ADE2) thereby allowing yeast to survive in media 
lacking the presence of histidine or adenine. (Fig.3). Yeast trans formant (pGBDhERαLBD) was 
grown overnight in 2mL of media lacking leucine and tryptophan (SC-LW) at 30°C with shaking 
at 300rpm. After growth, yeast was pelleted (4°C, 7min, 3700rpm,) media discarded and re-
suspended in 1mL of water. A second pellet was formed and re-suspend in 1ml of water before a 
45µL aliquot was added to 5mL of water. Media lacking histidine, leucine and tryptophan (SC-
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HLW with 0.1mM 3AT) was prepared and ligand-media mixes were made via dilutions from 
pre-made ligand stock solutions (10^-2 M) with a final concentration of 10µM.  The 
incorporation of 3AT (0.1mM) was necessary to suppress background arising from imidazole 
glycerol-phosphate dehydratase a key enzyme in the histidine biosynthetic pathway. In the case 
of dose responses serial dilutions were performed starting with 10 µM, solutions ranged from 
(10-5M-10-12M). Using a multi-channel pipetor 20µL of cells were added to 80µL of ligand in a 
96 well plate. To wells not containing cell: ligand mix, 80µL of water was added. Plates were 
incubated 48hrs (30°C and 300rpm) with optical density (OD) measurements recorded at 0, 24, 
48 hour intervals. Optical density readings were taken at a wavelength of 630 nm.   
Mammalian Cell Culture Assay 
Human embryonic kidney 293T (HEK293T) cells (ATCC, USA) were transfected with the 
plasmid pCMXwithERαLBD.  This plasmid contains the Gal4DBD (GBD) fused to the wild-
type ERα ligand binding domain LBD (GBD:LBD fusion under the control of a cytomegalovirus 
(CMV) promoter).  The reporter plasmid, p17*4TATAluc, contained the Renilla luciferase gene 
under the control of four Gal4 response elements located upstream from a minimal thymidine 
kinase promoter. The pCMXβgal, a plasmid containing the β-galactosidase gene under the 
control of the mammalian CMV promoter, was also used as an internal standard. Lipofectamine 
2000 (Invitrogen, USA) was used as the cationic lipid and transfection experimental details are 
described in Taylor et al.  Ligands were added to the wells at various concentrations.  Cells were 
harvested 48hrs after the addition of ligand and analyzed for luciferase and β-galactosidase 
activity.  All data points represent the average of triplicate experiments normalized against β-
galactosidase activity, standard deviations are represented using error bars.   
 In Silico Docking Studies 
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 Modeling of ligand-receptor complexes were carried out using AutoDock Vina®. The crystal 
structure of human estrogen receptor β was obtained from the research collaborator for structural 
bioinformatics (RCSB) protein data bank (PDB).  Ligands were created in ChemBioDraw Ultra 
13.0 transferred to ChemBio3D Ultra where they were minimized using MMFF84 force field and 
saved as pdb files. Ligands were modified with Auto Dock Tools by adding Gasteiger charges to 
set the partial charge of each atom and hydrogens on polar atoms. Ligand- receptor docking was 
viewed using the Pymol molecular graphics system.  
 
5.11 References 
1. Kuiper GC, Enmark E, Pelto-Huikko M, et al. Proc Natl Acad Sci USA 1996, 93(12), 5925-30. 
2. Warner, M., Huang, Bo. Gustafsson, Jan-Ake. Trends in Phamacological Sciences. 2017, 38 
3. Tiziano Tuccinardi, Giulio Poli, Marco Dell’Agnello, Carlotta Granchi, Filippo Minutolo, and 
Adriano Martinelli. J Enzyme Inhib Med Chem, 2015, 30(4), 662–670. 
 
4.  Chunyan Zhao, Karin Dahlman-Wright, Jan-Ake Gustafsson, Atlas Genet Cytogenet Oncol 
Haematol. 2009; 13(2) 201-203. 
 
5. Ascenzi, P.; Alessio, B.; Marino, M. Molecular Aspects of Medicine, 2006, 27, 299-402.   
6. Jia, M; Dahlman-Wright,K; Gustafsson, JA. Endocrinology & Metabolism. 2015, 29, 557-568. 
7. Lei CHEN etal. Acta Pharmacologica Sinica. 2014, 35, 1333–1341. 
8. John A. Katzenellenbogen J. Med. Chem. 2011, 54, 5271–5282. 




10. De Angelis M, Stossi F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. J Med 
Chem, 2005, 48,1132–1144. 
11. Filippo Minutolo,1 Marco Macchia, Benita S. Katzenellenbogen, and John A. 
Katzenellenbogen, Medicinal Research Reviews, 2011, 3, 364-442. 
 
12. Hua-Jun Luo, Kun Zou, Nian-Yu Huang, Jun-Zhi Wang, Wei-Qiao Deng. Med Chem Res, 
2013, 22, 4468–4480. 
13. McDevitt RE, Malamas MS, Manas ES, Unwalla RJ, Xu ZB, Millere CP, Harris HA. Bioorg 
Med Chem Lett. 2005, 15, 3137–3142. 
14.  Williams,C; Edvardsson, K; Lewandowski, SA; Strom, A.Oncogene, 2008; 27(7),1019-
1032. 
 
15. Chang, EC; Katzenellenbogen, BS. Endocrinology, 2006, 147(10) 4831-42. 
16. Julia Häring, Susanne Schüler, Claus Lattrich, Olaf Ortmann, Oliver Treeck, Gynecologic 
Oncology, 127 (2012) 673–676. 
 
17. Ilaria Paternia,1, Carlotta Granchia,1, John A. Katzenellenbogenb, Filippo Minutoloa, 
Steroids, 2014, 90, 13–29. 
18. Gangadhara R Sareddy, et al.  Chin J Nat Med, 2015, 13(11), 801-807 
19. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Steroids 2008, 73, 59–68.  
20. Weiser MJ, Wu TJ, Handa RJ. Endocrinology, 2009, 50, 1817–1825. 
21. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. J 
Med Chem, 2001, 44, 4230–4251.  
 





24. Richardson, T.; Norman, B.; Lugar, C.; Dodge, J. Bioorganic & Medicinal Chemistry 
Letters. 2007, 17, 5563–5566. 
 
25. Richardson, T.; Norman, B.; Lugar, C.; Dodge, J. Bioorganic & Medicinal Chemistry 
Letters. 2007, 17, 5082–5085. 
 
26. Richardson, T.; Norman, B.; Lugar, C.; Dodge, J. Bioorganic & Medicinal Chemistry Letters 
2007, 17, 4824–4828. 
 
27. Richardson, T.; Norman, B.; Lugar, C.; Dodge, J. Bioorganic & Medicinal Chemistry 
Letters, 2007, 17, 3570–3574. 
 
28. Filippo Minutolo,1 Marco Macchia, Benita S. Katzenellenbogen, and John A. 
Katzenellenbogen, Medicinal Research Reviews, 2011, 3, 364-442. 
  
29. M. Paz Otero, Alicia Torrado, Yolanda Pazos, Fredy Sussman, Angel R. de Lera. J. Org. 
Chem. 2002, 67, 5876-5882. 
 
30. Hinrich Gronemeyer, Jan-Åke Gustafsson, Vincent Laudet, Nature Reviews.2004, 3. 
  
31. Rebecca Skerrett a, Tarja Malma,b, Gary Landreth Neurobiology of Disease, 2014, 72,104 –
116. 
  
32. Bitoku Takahashi etal. Journal of Medicinal Chemistry, 2002, 45,16. 
 
33. Efrén Pérez, William Bourguet, Hinrich Gronemeyer, Angel R. de Lera. Biochimica et 
Biophysica Acta, 2012,18 (21), 57 –69. 
 
34. A Szanto, V Narkar, Q Shen, IP Uray, PJA Davies, L Nagy. Cell Death and Differentiation, 
2004, 11, 126–S143. 
 
35. Takemi Tanaka, Luigi M. De Luca. Cancer Res. 2009, 69,12.  
134 
 
36. de Lera,A; William,B; Lucia,A; Hinrich, G. Nature Reviews.2007, 6, 811.  
 
37. S. Chandraratna. J. Med. Chem. 1995, 38, 4764-4767. 
 
38. Eric Finzi, Michael J. Blake, Paul Celano, John Skouge, Renuka Diwan. American Journal of 






IINVESTIGATION INTO FLUORESCENCE AND BINDING 
 
6.1 Nuclear receptor probes 
A major component of targeting nuclear receptors and successfully eliciting a desired 
physiological response is understanding its distribution within subcellular compartments. While 
nuclear receptors are known to localize in the cell’s nucleus, receptors have been shown to exist 
in other areas such as the cytoplasm and mitochondria [1] then later translocating into the 
nucleus [2]. These findings open the door for the potential of targeting the nuclear receptor 
during different stages (pre or post translocation) however a clear understanding must be 
gathered on the nuclear receptors role outside of the cell’s nucleus.    
The vast implications of nuclear receptors in various diseases also strengthens the need for 
cellular tracking of them [3,4,5]. A better understanding of the receptors folding process in its 
native environment can provide insight into misfolding or constitutive turn on of receptors. As 
illustrated previously nuclear receptors undergo a cascade of events and a series of folding after 
ligand binding to turn on transcription all of which have a margin for error [6]. The ability to 
gain insight into the ligands role during conformation changes, the nuclear receptor response to 
the ligand and recruitment of co-activators can potentially aid in designing ligands with higher 
affinity.       
Understanding of nuclear receptor movements within the cell can aid in better ligand design, as 
well as advancing the understanding of nuclear receptors role in various diseases. Several 
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methods currently exist to aid in providing insight into the subcellular movements of nuclear 
receptors.          
6.1.1 Green Fluorescent Protein Fusion 
The discovery of GFP and its fluorescent variants has had a revolutionizing effect on most 
cellular visualization and trafficking applications. GFP fusion proteins have emerged as the most 
common and successful biotechnological application of GFP. Fluorescent fusion proteins have 
shown to boast several advantages over classical visualization probes such as GFP’s lack of 
toxicity (in most cases), lack of requirement for co-factors or substrates and lastly the large 
diversity of fusion probes that can be generated. A detailed list of GFP fusion proteins have been 
published by Tsien [7].  
Among the number of protein systems studied with GFP fusion are the nuclear receptors, of 
which several fusions have been made for the exploration of receptor mobility [8]. The ability to 
use GFP as a fluorescent tag successfully eliminated classical limitations and opened the door for 
advantageous in vivo subcellular trafficking. Several studies demonstrate the role and 
contribution that GFP has played in nuclear receptor mobility, compartmentalization, and ligand 
discovery with diverse nuclear receptors including GR, PR, and ER [9-11]. In general retention 
of transcriptional activity and ligand dependence is reported [12-15]. A disadvantage to fusion 
proteins specifically to the ligand binding domain is the potential interference with the ligand 
binding domain and the co-activator proteins essential for transcriptional regulation. Likewise, 
many probes are often bulky in size facilitating the previous disadvantage as well as a new one 
the decrease in affinity of the ligand to the receptor due to its steric bulk. Although subcellular 
visualization studies have been successfully conducted for several steroidal nuclear receptors the 
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possibility that tagging with GFP may disrupt some innate functions and localization of the 
natural receptor cannot be ruled out.                 
6.1.2 Classical Receptor Tracking  
Classically receptor trafficking in vivo has been monitored via radioactive isotopes, enzyme-
linked immunosorbent assay or ELISA and conjugate fluorescent dyes. While highly utilized, all 
the poses several limitations including radioactive hazards, fixation and incubation with 
antibodies and lastly size of the probe (Alexa Fluor® or DyLight Fluor®) [16].  
 
Figure 6.1 Commonly used fluorescent tags. Commercially available as kits both Alexa Fluor 
and DayLight Fluor are fluorescent tags used for visualization, however both add bulk to their 
host.   
 
Included in nuclear receptors that utilize traditional tagged ligands for monitoring are the 
estrogen receptors. Estradiol Glow [17], a fluorescent derivative of the endogenous ligand 17β-
estradiol is commercially available. Structurally estradiol remains intact however the A-ring 
phenol has been modified for the inclusion of the tag. As shown in figure 6.2 modification 
involved deprotonation of the hydroxy moiety abolishing its ability to function as a hydrogen 
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bond donor. Formation of an O-C bond now renders functionality to hydrogen bond acceptor. In 
contrast tagged estradiol probes exist that maintain all functional groups of 17β estradiol 
however contains a large sterically bulky tag. As illustrated in our work and the work of others 
[18] though the estrogen receptor LBP can accommodate larger volumes ideal ligands do not 
occupy the entire pocket. The dilemma inclusion of sterically bulky tags adds is disruption to 
native folding behavior of the protein thus creating a demand for a novel class of probe that co-
functions as fluorophore and ligand.      
 
Figure 6.2 Classical Estradiol Modified Probes. Estradiol-glow requires altering estradiol (red) at the A-
Ring phenol changing its functionality to a hydrogen bond acceptor as opposed to donor. The classical 







6.1.3 GFP inspired ligands as nuclear receptor probes 
One of the rationales for using the GFP chromophore as the scaffold for receptor agonist was our 
hypothesis that the intrinsic ability to fluoresce could be re-activated upon binding thus tying 
binding to fluorescence. If the chromophore inspired ligands could invoke florescence within the 
nuclear receptor as a direct consequence of binding a new type of probe could be established. 
This class of fluorescent probe would boast several advantages over traditional forms of cellular 
tracking including the elimination of sterically bulky attachments and the handling of radioactive 
tags. The primary benefit of such a class of ligand is the ability to monitor the nuclear receptors 
movement without disruption of the receptors innate interaction with the ligand allowing for both 
in vivo and invitro cellular tracking.   
6.2 GFP-Inspired ligands as nuclear receptor probes invivo  
The hypothesis that the GFP-chromophore inspired ligands could co-function as a probe was 
assessed by transfecting NIH3T3 cells with plasmid pCMXwithERαLBD. After 8 hours of 
incubation in humidified air at 37oC, cells were treated with select ERα active ligands and placed 
back in the incubator for 48 hours. At the end of 48 hours cells were removed washed with 
1XPBS and viewed via confocal microscopy for fluorescence. To establish a background a set of 
cells were not transfected, a set of cells were transfected however not treated with a ligand and 
lastly a set of cells were transfected and treated with solely the vehicle. A set of cells were also 
treated with the ligands in the absence of ERαLBD to ensure that any observed fluorescence is 
attributed to just the presence of the ligand. As a positive control estradiol glow a tagged 
derivative of estradiol that fluoresces red was used. Lastly as a negative control ligand CW33 
which has consistently shown no activation in ERα was used. Figure 6.3 below illustrates the 
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controls as the bright field image (left) and the image at the fluorescent image (right). Results are 







Cells + ERαLBD 









Cells + ERαLBD + Estradiol-Glow 
Cells + ERαLBD + CW33 







Figure 6.3 Confocal images of GFP-chromophore inspired ERα ligands. The above images 
illustrate controls along with images for ligands CW32 and CW28. Images are displayed as 
brightfield (left) and fluorescent (right).  
 
 
Analysis of the above images concluded that fluorescence was not observed in NIH3T3 cell line 
with the GFP inspired ERα top agonist ligand. Visualization studies were continued invitro via a 
collaborative effort with the Snell Lab. 
6.3 GFP-Inspired ligands as nuclear receptor probes invitro 
Cells + CW32 +ERαLBD 
Cells + CW28 +ERαLBD 
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In a collaborative effort pioneered by the Snell Lab to demonstrate that estrogen like receptors 
exist in the B.Manjavacas [19] a species of Rotifera several arylmethyleneimidazolone ligands 
were submitted for a series of invitro testing. It is important to note that ligands submitted for 
testing pre-date this work however they have previously been shown to behave as agonist for 
ERα (unpublished results) [20]. Ligands submitted for invitro testing aided in the design of the 
new synthetic ligands generated in this work so while they are not the strongest activators they 
are a viable representation of GFP-inspired chromophores as ERα agonist. To ensure that 
submitted ligands were interacting with an estrogen like receptor in rotifers several tests were 
conducted including a reproduction test in which at least two ligands show increase in off spring 
generated. Once confirmed that the ligands were indeed binding with an estrogen like receptor 
the rotifers containing treated with the ligands were viewed using confocal microscopy. Images 
for several ligands in vitro are displayed below in Figure 6.4.  
The results of figure 6.4 indicate that the GFP-inspired chromophore ligand can indeed be used 
both as a classical ligand and as a cellular tracking probe. Employed as a control estradiol-glow 
(red) certainly strengthens the hypothesis that estrogen like receptors are indeed present but also 
provides a template guide to locations in which this receptor could be located. Analysis of the 






Figure 6.4 Synthetic fluorescent ligands bind selectively within B. manjavacas neonates. Bright 
field confocal and merged microscopic images of rotifers treated with ER binding small 
molecules. The compounds bind primarily to the reproductive tissues, the vitellarium, and the 









The investigation into the correlation between fluorescence and binding yielded interesting 
results. While in vivo studies showed no fluorescence the same did not hold true for invitro 
studies. Several ERα agonist that predate this dissertation demonstrated (unpublished results) 
fluorescence during invitro studies with the microinvertebrate rotifera. The GFP-inspired 
chromophore ligands not only demonstrated fluorescence but displayed localized fluorescence in 
specific systems within the rotifer. While the ligands that exhibited fluorescence do not activate 
with the same level of intensity as the ligands developed during this dissertation the mere fact 
that activation and fluoresce were housed in the same compound is proof of concept that the 
GFP-inspired chromophore ligand can indeed serve dual functionality. The combination of both 
results suggest that ligands can bind and activate however may not fluoresce likewise ligands 
may bind and fluorescence. The interesting thing to note is if higher binding and activation is 
associated with lower ability to produce fluorescence.     
6.5 Materials and Methods 
NIH3T3 cells were transfected with plasmid pCMXwithERαLBD using Polyfect. After 8 hours of 
incubation in humidified air at 37oC, cells were treated with select ERα active ligands and placed 
back in the incubator for 48 hours. At the end of 48 hours cells were removed, aspirated and washed 
with 1XPBS and viewed via confocal microscopy for fluorescence. 
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CONCLUSION AND FUTURE WORKS 
 
7.1 Conclusions 
Nuclear receptors role as transcription factors has caused them to be implicated in diseases 
ranging from cancer to diabetes [1]. Modulation of these transcriptional on/off switches is ligand 
mediated therefore providing a potential route to promote response from transcriptional 
machinery [2]. The potential to control key physiological responses at a subcellular level via the 
introduction of a ligand makes nuclear receptors of pharmaceutical significance [3]. Due to 
nuclear receptors wide distribution within the body [4] and commonality in structural motif [5], 
it is imperative when designing ligands that selectivity is exhibited by the ligand for not only 
separate families of nuclear receptors but also different forms within the same family termed 
isotypes. 
Residing at the core of designing ligands that target nuclear receptors rest the interaction between 
the nuclear receptors ligand binding pocket and the ligand. Insight of the LBP has operated as the 
centerpiece for nuclear receptor binding research. Broadly, the LBP can be characterized as a 
cavity highlighted by nonpolar amino acid residues while possessing few polar residues. 
Divergent across receptors [6], varying in shape, size, volume and residues the disparity within 
the LBP provides the distinguishing element that allows differentiation between ligand features 
that are exchangeable from those that are indispensable. 
Among the nuclear receptors that have gained considerable attention are the estrogen receptors. 
Notable for their roles in cancers [7] several ligands have been developed that target the specific 
isotype estrogen receptor α. Katzenellenbogen has significantly contributed to what is 
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understood about the estrogen receptor and ligand relationship, providing revelation into 
necessary functionality of compounds that bind within the ligand binding pocket [8]. 
Katzenellenbogen’s devised pharmacophore for estrogen receptor activators highlights 
requirement of the phenol, flexibility within scaffold options (heterocyclic), and suggested 
substituents [9]. The ACD system pharmacophore Katzenellenbogen established has served as a 
blueprint for design of acceptable ligands with consideration to ligand size, volume, polarity, 
polar contacts.   
This dissertation illustrates the synthesis of a small library of GFP chromophore inspired ligands 
as estrogen receptor α agonist. Chapter 4 highlights the use of Katzenellenbogen’s 
pharmacophore as well as previous work conducted from our lab in this area to rationally design 
and evaluate additional GFP inspired ligands. Key findings include 10 ligands that serve as ERα 
agonist that were generated based on structural activity relationships from synthesis of multiple 
generations. Included within those 10 ligands are a super agonist CW32 that exhibits agonist 
behavior 235% that of 17β-estradiol the endogenous ligand for the receptor. Computational 
modeling using Auto Dock Vina supported rationale established for the successful agonistic 
behavior that careful consideration must be given to 1) hydrogen bonding network with the LBP, 
2) the size and volume of the ligand and lastly 3) the molecular topography of the ligand. 
Consideration to these guidelines supported that high activating ligands give priority to 
participating in hydrogen bonding with either key histidine, glutamine, arginine residues or 
backbone residues as in the case of CW32. Contributing to activation are ligand volume and 
molecular topography with successful ligands of this class producing higher activation at 
volumes comparable or lower than that of estradiol. Lastly ligands with smaller nonpolar, 
branched moieties produced higher activation than those without.  
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Once successful generation of a series of ERα active ligands had been established, Chapter 5 
illustrated the need for isotype and nuclear receptor selectivity. Key highlights of chapter 5 
include conformation of preferential activation of several compounds including the top two 
activators for ERα. TFERT findings also included conformation that our computationally 
modeled designed ligands indeed bind in the same ligand binding pocket as that of the estradiol. 
While some ligands activated both isotypes with preference, ligand CW72 exclusively activated 
ERα. Lastly ERα active ligands exhibit no activation in the additional nuclear receptors test.  
Understanding of binding, activation and receptor selectivity guided our use of the ligands as 
cellular probes. Originally inspired by the chromophore of the GFP Chapters 6 highlights the 
uses of these ligands as in vivo and in vitro probes for cellular tracking of nuclear receptors. Key 
highlights include the successful demonstration of this class of ligand to serve as both a 
binder/agonist and a fluorophore in vitro. Globally these findings support the hypothesis that 
GFP chromophore inspired ligands can co-function as both the stimuli and the probe. With the 
availability of other fluorescent protein chromophores and the broad range of available nuclear 
receptors this opens the door to a new class of ligand.         
 
7.2 Future Works 
 
While this dissertation covers a good breadth of work in the synthesis, biological evaluation and 
cellular application of GFP chromophore inspired ligands specifically for estrogen receptor α 
work remains to be completed. Future work can be separated into two categories 1) enhancement 




To further the development of this class of ligand priority should be given to assessing the 
remainder of the ERα active ligands in TFERT assay against both isotypes. It is possible that 
other ligands exist in the set that are completely exclusive for ERα. Completion of this study will 
allow for a 3rd generation lead ligand that demonstrates complete selectivity for ERα currently 
that new lead would be CW72. While a drawback of CW72 is it low activation it is the only 
ligand thus far to show complete specificity for ERα. Consideration should be given on how to 
enhance binding and activation of CW72 while maintaining specificity. Concurrently due to 
CW32 high level of activation consideration should be given on understanding what makes 
CW72 specific and incorporating those features into CW32 will maintain super agonistic 
activation profile. Lastly with respect to ligand development the scope of this dissertation only 
covered agonist behavior however the same library of ligands should be screened for antagonist 
behavior. Antagonist, while they may elicit a different response, still bind and orient themselves 
in the ligand binding pocket providing more insight as to the development of optimal binders for 
this class of compound.   
Development of cellular tracking and visualization should initiate with the revisiting of the 
current active set of ERα agonist. While initial in vivo visualization studies were conducted at 
various concentrations and different incubation times test, was limited to one cell line NIH3T3. 
The assay should be reconducted in an additional cell line specifically HEK293T. If accessible 
CW32 and CW72 should be submitted for in vitro testing in rotifera testing; CW32 due to its 
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CW1 355 422 
CW2 351 446 
CW3 355 424 
CW4 355 432 
CW6 355 446 
CW7 360 438 
CW8 360 424 
CW9 345 425 
CW13 355 456 
CW15 360 452 
CW16 355 500 
CW18 345 425 
CW20 360 430 
CW22 355 414 
CW23 355 452 
CW41 355 420 
CW42 360 424 
CW43 360 426 
CW46 360 432 
CW47 360 452 
CW54 360 426 
Napthyl Core 
 
CW48 368 435 
CW49 363 452 
CW50 369 431 
CW51 370 429 
CW57 349 449 
CW59 369 429 
CW60 368 455 
N-propyl 
  
CW24 369 439 
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CW25 378 455 
CW29 355 444 
CW30 382 600 
CW33 348 429 






CW27 380 450 
CW28 372 445 
CW31 353 440 
CW32 382 445 
CW72 357 510 
N-phenol 
  
CW34 370 451 
CW36 371 445 
CW39 368 455 
CW61 384 600 
CW63 402 577 
CW81 382 605 
CW82 357 504 
N-Cyclic 
  
CW35 374 451 
CW38 370 457 
CW68 399 569 
CW69 401 571 
CW76 383 600 
CW77 384 600 
N-Chiral 
  
CW40 370 447 
CW55 374 449 
CW84 370 451 
CW85 370 595 
CW86 370 455 
CW90 396 567 
CW91 370 483 
CW92 375 451 
CW93 357 446 
CW95 357 450 
154 
 
CW96 383 450 
CW97 383 595 






SPECTRAL CHARACTERIZATION OF ACTIVE LIGANDS 
 
CW28 
1H NMR δ: 1.46 (d, 6H, C(CH3)2), 2.41 (s, 3H, N=C-CH3), 4.21-4.30 (m, 1H, N-CH), 6.82 (d, 2H, 
Ar-H), 7.02 (s, 1H, C=C-H), 7.99 (t, 2H, Ar-H). Calculated MS (ESI): 245.1 [M+H]+ 
CW29 
1H NMR δ: 1.09 (t, 3H, C-CH3), 1.75-1.83 (m, 2H, CH2), 2.49 (s, 3H, N=C-CH3), 3.70 (t, 2H, N-
CH2), 6.98 (d, 1H, Ar-H), 7.36 (s, 1H, Ar-H),  7.39 (t, 1H, Ar-H) 7.55 (d, 1H, Ar-H) 7.94 (s, 1H, 
C=C-H). MS (ESI): 245.1 [M+H]+ 
CW30 
1H NMR δ: 1.85 (t, 3H, CH3), 1.62-1.74 (m, 2H, CH2), 2.38 (s, 3H, CH3), 3.59 (t, 2H, N-CH2), 
6.81 (t, 1H, Ar-H), 6.92 (d, 1H, Ar-H), 7.15 (s, 1H, C=C-H), 7.31-7.39 (m, 2H, 2Ar-H). 13C NMR: 
MS (ESI): 245.1 [M+H]+  
CW32  
1H NMR δ: 1.46 (d, 6H, (CH3)2), 2.39 (s, 3H, N=C-CH3), 4.25 (m, 1H, N-CH), 6.82 (t,1H, Ar-H), 
6.93 (d, 1H, Ar-H), 7.07 (s, 1H, C=C-H), 7.27-7.33 (m, 2H, 2Ar-H). MS (ESI): 245.1 [M+H]+ 
CW34   
1H NMR δ:2.11 (s, 3H, N=C-CH3), 6.82-6.85 (dd, 5H, Ar-H), 7.12 (dd, 2H, Ar-H), 8.08 (d, 2H, 




1H NMR δ: 1.49-2.03 (m, 8H, (CH2)4), 2.47 (s, 3H, N=C-CH3), 4.21-4.34 (m, 1H, N-CH), 6.79 (d, 
3H. Ar-H), 8.02 (d, 2H, Ar-H, C=C-H). MS (ESI): 271.2 [M+H]+ 
CW38 
1.12-1.39 (m, 2H), 1.59-1.79 (m, 5H), 1.95-2.17 (m, 2H ), 2.38 (s, 3H, N=C-CH3), 3.61-3.77 (m, 
1H, N-CH), 6.81 (d, 3H, Ar-H), 8.02 (d, 2H, Ar-H, C=C-H). MS (ESI): 285.2 [M+H]+ 
CW39 
1H NMR δ:2.13 (s, 3H, N=C-CH3), 3.79 (s, 3H, OCH3), 6.80-6.83 (dd, 5H, Ar-H), 7.14 (dd, 2H, 
Ar-H), 8.11 (d, 2H, Ar-H, C=C-H). 13C NMR: MS (ESI): 309.1 [M+H]+ 
CW61 
1H NMR δ:2.13 (s, 3H, N=C-CH3), 6.81 (d, 2H, Ar-H), 6.84 (d, 2H, Ar-H), 7.12 (d, 2H, Ar-H), 
8.07 (d, 2H, Ar-H, C=C-H). MS (ESI): 295.2 [M+H]+ 
CW63 
1H NMR δ:2.38 (s, 3H, N=C-CH3), 6.12 (s, 1H, Ar-H), 6.21 (d, 1H, Ar-H), 6.82 (d, 2H, Ar-H), 
7.12 (d, 2H, Ar-H), 7.18 (d, 1H, Ar-H), 8.23 (s, 1H, C=C-H). MS (ESI): 311.2 [M+H]+ 
CW72 
1H NMR δ: 1.47 (d, 6H, C(CH3)2), 2.41 (s, 3H, N=C-CH3), 4.23 (m, 1H, N-CH), 6.71(d, 1H, Ar), 
6.83 (t, 1H, Ar-H), 7.11 (d, 1H, Ar-H), 8.01 (s, 1H, C=C-H).  MS (ESI): 261.1 [M+H]+ 
 
